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Abstract
This thesis describes the development of a novel platform for targeted directed
evolution, designed to operate entirely in vivo. The system comprises a fusion of T7
RNA polymerase and activation-induced deaminase (AID); targeting is achieved by the
placement of the sequence of interest under the control of a T7 promoter, whereby
transcription by the polymerase exposes the DNA to mutation by the AID moiety of
the fusion. The localisation effect serves to target mutation to the area downstream of
the promoter, and increase the rate of that mutation compared to non-directed
background activity. The system, and appropriate controls and targets, are constructed
and tested in a plasmid-based experimental work-fow. The targets are, further,
integrated into the genome of Escherichia coli to alow high-throughput analysis of the
mutation rate of a single copy target. Nucleotide sequencing is used to confrm both
enhanced mutagenesis of the system, and a high degree of targeting. The system is then
applied to a test case, diversifcation of a transcription factor (LasR from Pseudomonas
aeruginosa, encoded by the lasR gene), with an eye to producing an orthogonal
signal/response pair with promoter PLas. A logic gate-based flter is designed and
constructed to alow tight moderation of a feedback loop to control the mutator,
alowing it to be 'shut off' once desired function is exhibited by the target protein.
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1. Introduction
Life on Earth, with al its intricacies of function, with al its divergences and
convergences, has been produced by a fundamental process: Evolution. Variation
introduced by the constant, incremental mutation of the genetic code at the heart of al
organisms alows new functions to develop from old ones or entirely paralel ones to
appear. The elegant simplicity and power of the process make it only natural that we
should attempt to control and direct it.
This thesis presents a new approach to harnessing the potential power of evolutionary
processes. The introduction wil frst defne directed evolution and provide an overview
of current techniques and approaches that are employed in that feld, then progress to a
review of studies on Activation Induced Deaminase (AID) and T7 RNA polymerase
(T7 RNAP) which are enzymes that have relevance to the work presented. 
1.1. Directed evolution
The attempt to produce new function, or an improvement in current function, in a gene
or protein within the laboratory via mimicry of the process of natural selection is
termed directed evolution. Applying the principles of the natural process, the genetic
sequence encoding the target is altered (diversifed) either by direct mutation of the
DNA or some other method of introducing variability (for instance, gene shufing).
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Screening of the sequences thus produced, with selection of candidates based on
proximity to the target phenotype, alows promising candidates to be subjected to
further rounds of selection. These cycles of mutation/variation, screening and selection
alow the experimenter to actively “evolve” the genes in question toward the desired
phenotype.
Directed evolution-based strategies are most commonly employed in protein engineering
projects, when the aim is to achieve to enhance efciency of a desired process; proteins
may be engineered for increased activity, improved stability, greater specifcity or a
relaxation of same, or some other desirable attribute (Romero 2009). In the ideal case,
a protein would be rationaly designed and constructed to incorporate the desired
improvements – this requires comprehensive data about the structure, folding and
molecular interactions within the target protein, however, which are rarely available.
The feld of computational protein design (reviewed in Hilvert 2013; Kiss 2013) aims to
rationaly engineer proteins, but although great advances have been made in optimising
existing proteins and creating new functionality (Tinberg 2013) the process is far from
solved (Schreier 2009). Though protein design projects are often complemented with
directed evolution approaches (Röthlisberger 2008), they fal outside the scope of this
project.
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Directed evolution may also be used to 'tune' genetic circuits, or adjust regulatory
elements within a stretch of DNA incorporating one or more genes (Cobb 2013). Even a
circuit designed and built using wel-characterised elements, about which many of the
defning parameters are known, is subject to unpredictable behaviour as a result of host
compatibility, noise, and changes in celular environment (among other confounding
factors). This is a problem particularly in the feld of Synthetic Biology, which – via
standardisation of techniques and characterisation of parts and devices – aims to make
biology easier to engineer; more predictable behaviours leading to more reproducible
results. Emergent effects arising from the combining of a number of parts, even wel-
known parts, conspire to reduce predictability of a system as the complexity of that
system increases (Canton 2008). Directed evolution of circuits, while divergent from the
'standardisation' aim of the feld, could help tune systems toward their predicted and
desired operation post-construction – for instance, to maximise the output of a reporter
gene within a complex biosensor. Variants or libraries of parts can also be produced,
alowing for more fexibility of design; either by offering alternatives in e.g. promoter
strength, or by creation of orthogonal signaling systems, for example, to eliminate
'cross-talk' (where two such systems interfere with each others' operation) and alow
repeated use of a useful control element (Morey 2012).
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Current methods for directed evolution generaly folow an archetypal cycle, shown in
fgure 1. Typicaly, rounds of mutation are carried out in vitro prior to insertion of
DNA into cels for screening and selection. There is an inherent inefciency to this
process, however, as the number of DNA sequences successfuly incorporated into cels
is a reduction of several orders of magnitude from the number produced in the
mutation step. Thus, only a few thousand sequences wil reach the screening step from
an original pool of milions, or even bilions of genetic variants. Further, those
candidates which most closely approach the phenotype being screened for each round
must be favoured in the selection process, meaning that escaping 'local peaks' and
crossing ftness valeys to a more effective variant is difcult (Romero 2009); see fgure 2
for an ilustration of such a case. Extended diversifcation times are required to escape
a local peak, but the efciency limitation introduced by transformation means that
successful incorporation of a superior variant of a gene into a cel for selection is
unlikely.
Current methods for directed evolution usualy involve one or more in vitro steps. A
review of both those methods that take place exclusively in vitro and those that utilise
a mixture of in vitro/in vivo steps wil be presented here, folowed by an examination of
the more restricted feld of purely in vivo systems for directed evolution.
12
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Figure 2: Directed evolution explores a 'sequence space'
A protein library from a pool of diversified DNA may be visualised as occupying a
'fitness landscape'. Fitness describes the ability of the protein to perform a desired
function, with a higher peak (lighter colour in this figure) indicating a more fit protein
variant. Most sequences wil not function (black area), and functional sequences
(coloured) wil cluster with other functional sequences – i.e. fuly-functional sequences
may arise via less functional intermediates. Transitioning from one peak to another
may result in a more fit protein but requires movement through a 'fitness valey'.
Directed evolution methods which only search for iterative improvements to an original
sequence (seeding a second cycle with successful variants from the first, for example)
may never identify a discrete peak which may produce a more fit protein.
Figure & legend adapted from Romero 2009.
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1.1.1. Pure in vitro methods
There are a smal number of methods for directed evolution which do not involve cels
at al – namely, mRNA (Xu 2002) and ribosome (Hanes 1997) display. In these
methods a set of nucleic acids, diversifed so that the resulting proteins expressed from
them display a wide range of sequence variation, are scanned. They are then screened
to select for binding afnity to a desired target ligand. The central problem with a
purely in vitro system is the linking of phenotype – which is selected for – and the
corresponding genotype. In in vivo systems the DNA encoding a successful protein is
contained within the cel with it, establishing a link between a successful mutant and
its sequence.  The in vitro display methods rely on fusion of the protein/mRNA
complex by puromycin-induced translation abortion (in the case of mRNA display), or
the isolation of the protein/ribosome/mRNA complex (ribosome display), to create a
physical link between protein variants and their encoding nucleic acid sequence. This
alows the linking of successful phenotypes to their associated genotypes, and retains
the genetic code responsible for producing the protein for purifcation.
These 'display' methods alow optimisation of single proteins with high efciency, given
that selection may be performed in vitro. This alows the screening of a signifcantly
larger number of sequences than those methods which incorporate an in vivo selection
step, as screening and selection are applied directly at the molecular level without the
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need to culture and examine cels. Display methods are particularly attractive for the
evolution of proteins which are deleterious or deadly to cels (Spirin 2004), but may not
be used for pathway evolution, for example, as the linking of phenotype and genotype
cannot work beyond a single gene. Additionaly, proteins which rely on an intra-celular
environment to fold or function properly are not amenable to optimisation via in vitro
methods. These methods sacrifce fexibility for great gains in efciency within their
narrow scope.
1.1.2. Mixed in vitro/in vivo methods
An abundance of approaches exist that utilise a mixture of both in vivo and in vitro
steps (Lutz 2004), and these mixed methods are certainly the most common approach
to directed evolution and protein engineering. Typicaly, the diversifcation of DNA
occurs in vitro, and the subsequent steps of screening and selection take place within
cels. The expression of proteins in the celular context means they may be selected
based on how they act in the native environment; this eliminates the possibility of a
promising candidate selected in vitro not translating to a successful in vivo expression.
Common approaches to the diversifcation of nucleic acid sequences in mixed directed
evolution methods include error-prone PCR, recombination in vitro and oligonucleotide-
directed randomisation. The resulting pools of diversifed DNA are then transformed
into cels, for screening and selection.
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A notable strategy that diverges from these standard methods is phage display
(reviewed in Fernandez-Gacio 2003). Here, the genotype and phenotype are linked via
the integration of the diversifed library into a gene encoding a coat protein of a phage.
Upon assembly of the coat, a variant of the library of proteins is displayed upon the
coat. A desired target for interaction is then immobilised on a matrix. Phage which
display a protein variant which can bind to the target wil remain after washing the
rest of the pool away, and may subsequently be cleaved and eluted. Enzymes may be
selected for by the use of substrates which break down into strong inhibitors, thus
trapping any enzymes which successfuly cleave the target; in both cases, the
transformation of successful phage particles into Escherichia coli alows the propagation
of relevant genes for sequencing. The library may be panned in cycles to determine the
strongest interactors, and those subjected to more rounds of diversifcation – the
efciency of screening is limited by the phage titre achievable, as wel as the
transformation efciency.
These mixed methods are susceptible to a loss of efciency during the transformation
step, as mentioned earlier in this text. The transfer of the sequence pool generated by,
for example, error-prone PCR into the host cels for screening and selection is a
relatively inefcient process. While bilions of diverse sequences may be produced in the
PCR reaction, transformation and screening wil limit the number of sequences for
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selection to at most several hundred thousand sequences – even in a scenario involving
high-throughput screening by fuorescence-activated cel sorting (FACS), for example.
An additional layer of inefciency is introduced by the time-consuming nature of the
protocol – transferring back and forth between cels and in vitro environments is time-
and often labour-intensive.
1.1.3. Pure in vivo methods
The facilitation of directed evolution within living cels is most simply accomplished by
the incorporation of the target DNA into a strain possessing a mutagenic phenotype.
One example is E. coli XL-1 Red (Greener 1994, 1996), which derives its mutagenic
phenotype from the mutations in the mismatch repair pathway, the oxo-dGTP repair
pathway, and the 3'—5' exonuclease subunit of DNA polymerase III. The strain
therefore does not strictly increase the incidence of mutation events, but reduces the
number of those which are repaired to wild-type. Transfer of a target plasmid into such
a strain via transformation causes accumulation of mutations over many generations
with a low frequency: It is reported by Greener et al that the rate is approximately 1
mutation every 30 generations for a 2,000 bp plasmid within the XL-1 Red host. 
While this can result in optimisation of a target protein (for example, Bornscheuer
1998), the smal sequence space explored restricts the strain to minor optimisations
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rather than more major adaptation. More mutagenic strains encounter a trade-off
between accelerated evolution of a target, and faster decline in health of the cels in the
population as mutations accumulate within their genomes. One extension of this idea
utilises repression of the repair genes via induction of antisense RNAs, based on a
plasmid, which silence the genes in question (Nakashima 2009). This alows
mutagenesis to occur in response to an inducer, rather than continuously, and was
shown to increase mutation frequency by 2,000 fold over background. The lack of a
targeting method, meaning the mutagenic effect does not discriminate between the
intended target and the cel's own DNA, wil stil result in a decline in ftness of the
host over time. This necessitates re-transformation of the plasmids into a new set of
cels, bringing along with it the very inefciency in vivo methods seek to avoid.
One promising method which is reminiscent of the in vitro display methods mentioned
above, is phage-assisted continuous evolution, or PACE (Esvelt 2009). This method
utilises a global mutator strain of E. coli in continuous culture to perform the
diversifcation step of the directed evolution cycle – screening and selection of members
of the target library, however, are carried out by M13 bacteriophage. Target genes are
initialy diversifed, and the members of this library are packaged onto the genomes of a
phage population defcient in protein III. Phage lacking pIII suffer a 108-fold reduction
in infectivity; protein III is introduced by transformation into the mutator strain on an
18
accessory plasmid. The production of protein III from the plasmid is then linked to the
degree of function of the target gene. Upon infection of the mutator cels, phage
harbouring successful variants wil therefore replicate more efciently; as the phage
continuously infects mutator cels, reproduces, repackages (possibly after incorporating
further variation) and exits the host, library members wil proliferate more successfuly
in line with their functionality. This method may theoreticaly be used to diversify and
screen any sequence which may be linked to the transcription of protein III, or the
replication of M13 phage in general, and its main advantage is its continuous nature.
This alows exploration of a sequence space with no upper bound, beyond the time
limit set on the culture procedure – in the test case, T7 RNA polymerase was
diversifed and 200 rounds of protein evolution were performed over eight days,
resulting in a number of interesting variants of the target.
An in vivo method which involves direct targeting of mutation is described by Camps
et al (2003). It utilises a variant DNA polymerase I (PolI), modifed to be more prone
to error than its native counterpart, to introduce mutation during the replication step
of DNA. In E. coli the frst ~500 nt of DNA synthesised during replication are done so
by PolI, with the remainder completed by DNA polymerase III: The authors took
advantage of this 'specifcity' by co-transforming a cel with one plasmid containing
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their variant PolI and another – which relies on PolI for replication – containing a
target sequence immediately downstream of the origin of replication.
The authors expected to see increased mutation in the stretch of DNA replicated by
PolI; that is, the frst ~500 bp folowing the site of replication initiation. In fact, they
saw greatly increased mutation evenly along the frst ~700 bp, and an increase in
mutation over background up to 3.7 kb into the plasmid sequence. They report an
average of 8.1 × 10–4 mutations per base pair for that stretch of sequence, or an
increase of 80,000 times when compared to the native PolI. The method is therefore
powerful for achieving targeted mutation of sequences based on plasmids.
While altering the mutagenic activity of the chassis (herein defned as the host
environment, usualy a prokaryotic cel but not necessarily) is one approach, others
involve more active engagement in the process of diversifcation. Perhaps the most
prominent example of such a method is multiplex automated genome engineering – or
'MAGE' (Wang 2009). MAGE uses a specifc chassis strain (E. coli EcNR2) which
expresses  a single-stranded DNA (ssDNA) binding protein from bacteriophage. This
alows incorporation of oligonucleotides introduced into the cel into homologous areas
of the genome while it undergoes replication; diversifcation of a pool of oligonucleotides
bearing homology to the target sequence beforehand means that variation may be
introduced into the genome in this manner. By carrying out several cycles of
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introducing pools of diversifed oligonucleotides and alowing DNA replication and cel
division, Wang et al caused one third of cels in the population to take up some variant
of the target sequence.
By adjusting one or both of the level of diversity represented in the oligonucleotide pool
and the cycle count, the scope and efciency of the generation of diversity within the
target or targets may be tuned. As a test case, Wang et al demonstrated a 5-fold
increase in the production of a target molecule – lycopene – after 3 days of continuous
cycling. In this case, 24 genes in the lycopene production pathway were targeted
simultaneously for diversifcation, toward the overal optimisation of the whole pathway
itself. Each target gene was found to be different from wild type in the successful
strains, with four genes targeted for knockout showing reduced or absent activity. This
multi-gene targeting approach alows pathways to be optimised, with a large sequence
space able to be explored; up to 15 × 109 variants are able to be generated over 35
cycles.
Outside the realm of prokaryotic chassis and systems, a number of eukaryotic methods
for in vivo directed evolution are being developed – or have already been used to some
degree of success. Of particular relevance are the development of mutagenic strains
based on the cytidine deamination activity of AID. By over-expressing AID and
simultaneously suppressing repair pathways, DNA near AID target sites undergoes
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increased mutation. By integrating targets near these sites, mutation can be promoted
with a degree of targeting. Somatic hypermutation caused by such expression of AID in
a chicken cel-line modifed to impede repair has been used to diversify a GFP gene
(Arakawa 2008). The GFP was integrated proximal to an AID target site, with the
analysis of the resulting mutations being used to engineer GFP to produce variants
with increased brightness – up to threefold.
1.2. Developing a system for in vivo directed evolution
An extremely powerful variant of directed evolution, therefore, is that subset of
techniques that takes place entirely in vivo. A robust in vivo method should alow
efciency to be maintained between stages or cycles of a directed evolution protocol,
alowing the use of long diversifcation times. Coupling this with selection in real-time,
i.e. in paralel with diversifcation, would alow the exploration of a much broader
sequence space, potentialy meaning more non-local peaks could be discovered. A
common drawback of pure in vivo approaches to directed evolution which currently
exist is the inherent 'background' damage that the host genome undergoes when cels
are exposed for extended periods of time to whichever mutagenic approach is used in
the technique. This research project examines the feasibility of using a protein-based
device to effect mutation in vivo in a targeted manner – i.e., the restricting of
mutagenesis to the target sequence and minimising its contact with, and impact on, the
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host genome. Before introducing the design of the system, the individual components
wil be introduced to provide contextual information as to why they were chosen.
1.2.1. Activation-induced deaminase (AID)
AID is a protein which plays a role in the immune system of higher organisms –
specifcaly, in somatic hypermutation or the diversifcation of antibodies. It thus
already operates as a mutator in nature and is a good candidate for the mutagenic part
of the fusion protein.
AID was discovered in 1999 by Muramatsu et al, and was thought at frst to target
RNA. Later studies in E. coli determined that it actualy acted on DNA (Petersen-
Mahrt 2002) via deamination of cytosine residues to uracil (Sohail 2003) – these errors
may then be corrected by the base-excision repair (BER) pathway. In the case of AID
mutation, uracil DNA glycosylase (encoded by ung) produces an abasic site by excising
the uracil from the backbone. An AP lyase may then cleave at the abasic site, alowing
it to be repaired. If not excised by uracil DNA glycosylase, the mismatch wil result in
the incorporation of a deoxythymidine at the site during replication. As a result of this,
AID commonly induces point mutations of C to T in DNA, but may cause more varied
mutation rates at reduced frequencies.
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AID can only bind to – and act on – ssDNA (Dickerson 2003; Pham 2003). Double-
stranded DNA (dsDNA) undergoing transcription exposes each strand, however, so
AID may act on dsDNA that is actively being transcribed. Sohail et al (2003) and
Ramiro et al (2003) found that AID acts with greater efciency on targets which are
highly transcribed. These studies demonstrated that a kanamycin resistance gene
engineered to knock out function reverted to function 20- (Ramiro 2003) to 50-fold
(Sohail 2003) more often when it was actively transcribed in a cel expressing AID –
and that if expressed in vitro under the control of a T7 promoter, that frequency
reached 300-fold (Sohail 2003).
AID has been identifed as exhibiting preferential binding to transcription bubbles and
similar structures (e.g., hairpin loops) as opposed to linear ssDNA (Larijani 2007).
After binding to DNA it acts processively, and may thus cause several mutation events
before disengaging (Brar 2008; Pham 2003). A 15-fold preference for the non-
transcribed strand was found to be exhibited by AID in a 2003 in vitro study by Pham
et al., who showed that the transcribed strand is 'protected' to a degree from action by
AID due to its hybridisation with RNA. The same study also uncovered a preference
for action at particular DNA motifs; that is, that AID shows some degree of sequence-
dependency. This is consistent with its activity in somatic hypermutation, where it is
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more likely to act at hotspots, although this is maintained to be an artefact of reaction
conditions by other investigators (Sohail 2003).
AID is a close relative of proteins in the APOBEC family (Bransteitter 2009) of
cytidine deaminases. A number of APOBEC proteins are active as dimers or other
higher-order oligomers (Prochnow 2007), and tetrameric AID has been purifed and
shown to cause deamination in vitro consistent with its activity (Dickerson 2003).
Mutations posited to interfere with oligomerisation, as informed by comparison to
solved structures of APOBEC-2, a close relation, caused a decrease in the ability of
AID to cause deamination (Prochnow 2007).
Whether oligomerisation is a requirement for the maintenance of  functionality (in ful
or in part) has as of yet not been elucidated, and is a contentious area within the feld
(see Sacho 2008). A study by Brar et al (2008) used atomic force microscopy to
demonstrate that AID has catalytic activity as a monomer, and does not aggregate
within transcription bubbles – other researchers contest these data, however, and the
ful truth is yet to be determined.
1.2.2. T7 RNA polymerase (T7 RNAP)
First isolated almost half a century ago from Type 7 (T7) bacteriophage (Chamberlin
1970), T7 RNAP has since become a workhorse in the felds of molecular biology and
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biotechnology. It exhibits high specifcity and afnity for its promoter (PT7), only
initiating transcription where this promoter is found and not from other sequences –
likewise, PT7 does not bind native RNA polymerases so can only alow transcription in
the presence of T7 RNAP. Transcription is highly efcient, progressing at a rate 5 times
that of E. coli's native RNA polymerase (Chamberlin 1973; Golomb 1974).
This increased activity over native polymerases can result in a large number of RNA
transcripts, so that even a smal number of active T7 RNAPs may cause saturation of
the cel's translation machinery – this was demonstrated in cels transformed with a
T7-driven protein expression cassette on a multicopy plasmid by Studier (1986).
Termination efciency at sequences which effectively terminate transcription by other
polymerases is often markedly lower for T7 RNAP (Jeng 1990), and variants of T7
RNAP have been characterised that read through an even larger set of terminator
sequences (Lyakhov 1997). T7 RNAP wil transcribe continuously in a stable manner if
not terminated, and may run ful-circle around an expression plasmid many times over
(Studier 1986).
The polymerase itself consists of only a single subunit, and does not require additional
cofactors to initiate and complete successful transcription (Sousa 1993). The
combination of high efciency and structural simplicity, along with the relative
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orthogonality granted by the promoter/polymerase specifcity pairing, make it an
excelent candidate for the abundant expression of a target gene.
1.2.3. Coupling DNA deamination to specific transcriptional
activity
The central aim that is presented in this thesis is to provide spatial and temporal
coupling of AID activity to a transcription bubble in a specifc manner. This has been
approached by creating a fusion protein of AID and T7 RNA polymerase using a
modular, extendable linker. Figure 3 shows a schematic representation of the system.
Expression of the mutator protein in a cel with a target gene downstream of a T7
promoter should cause a high rate of transcription of that target by the fusion protein,
during which single-stranded DNA in the transcription bubble wil be exposed to the
mutagenic AID moiety. The localisation of the AID molecule, along with the high
transcription rate of the target, should result in a greatly elevated mutation rate above
the background rate of the cel. As an added beneft, the constant strong expression of
the target ensures that the cel's phenotype is kept 'up-to-date' with its changing
genotype, which is key for effective selection strategies – successful candidates may be
selected more accurately and those which mutate 'past' a desired peak wil not be
included (or may be selected prior to this occurring, if selection is in real-time).
27
28
Figure 3: Schematic representation of the system
Top: The T7 RNA polymerase is fused to the AID moiety by a flexible polypeptide
linker. The polymerase wil transcribe target DNA downstream of a T7 promoter.
Botom: AID may interact with the ssDNA in the transcription bubble, causing
deamination of the target DNA.
RNA transcript
Target DNA
AID moiety of fusion
T7 RNAP moiety of fusion
Flexible linker
AID causes mutation at open complex
1.2.4. Targeted deamination in context
The T7-AID fusion should demonstrate several advantages over the in vivo methods
described in the literature.
Error-prone Polymerase I can only cause mutations within a short stretch of DNA;
furthermore, mutation frequency along that length is biased/skewed toward the start
and tails off as the distance from the initiation site increases (Camps 2003). This means
that this method may not be used to efciently and reliably mutate larger genes, or
operons, with ~3.7 kb being the apparent upper limit before the mutation frequency is
not signifcantly higher than background.  In contrast, the T7-AID fusion system
should be able to cause mutations along great lengths of DNA. T7 RNA polymerase
has been shown to transcribe an entire expression plasmid several times over if left
unterminated (Studier 1986). The addition of further T7 promoters evenly spaced along
a sequence, or a reverse promoter at the end of the target sequence, would be a trivial
way to increase consistency of mutation along an arbitrary length of DNA. Indeed,
bacterial terminators may be engineered to alow T7 RNA polymerase to pass through
unhindered (Jeng 1990) while stil retaining good termination efciency, meaning that
stretches of DNA including transcriptional terminators would not necessarily hinder the
fusion.
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Another signifcant disadvantage of the modifed PolI approach is that it may only be
used in a plasmid-based system. While a plasmid-based system presents more copies of
a target for diversifcation, it also serves to obfuscate the linkage of genotype and
phenotype that is the advantage of in vivo screening and selection. Mutations leading
to a desirable phenotype wil originate in only a subpopulation of the plasmids in the
cel; this may be masked by other plasmids, or may be 'outcompeted' and the
successful candidate lost.  While this is not an issue for strict gain of function
mutations, it prevents the approach from being used for diversifcation of function. In
contrast, the T7-AID fusion system is amenable to the evolution of targets both in
plasmids and integrated in single-copy within the genome of a chassis. This alows for
much more fexibility in the type of mutations that may be screened for.
MAGE may be used to target genomic DNA – indeed, it requires integration of targets
– and may be used to diversify several targets at once. Those targets need not be in
series, and the targeting is such that there is very little risk of diversifcation in non-
target sequence. The primary disadvantage of MAGE is in the initial construction of
libraries of variants of each target; these must be large, and are generated in vitro. An
analysis by the authors of the cost estimated that the price of oligonucleotides required
to alow fuly-degenerate diversifcation of 27 base pairs at one target site was only $30
at the time of writing (Wang 2009), but the time factor is not included in that analysis.
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Longer sequences or pathways, while generaly not needing to alow ful degeneracy,
increase costs further.
Both PolI and MAGE are not applicable in a eukaryotic context. In vivo directed
evolution of genes in eukaryotes which may rely on folding or post-translational
modifcation impossible in prokaryotic chassis can not be approached by those
techniques. In contrast, the T7-AID fusion may be amenable to use within a eukaryotic
context. As described earlier, methods exist which utilise the activity of AID in
eukaryotic cels to achieve directed evolution, and T7 RNA polymerase – along with
associated promoters and terminators – retains function and specifcity within
eukaryotic cels (Lieber 1989).
The fusion system offers an approach that may be used to optimise a target on a
plasmid or on the genome, and within both pro- and eukaryotic hosts. Additionaly it
does not involve the strenuous set up associated with a MAGE run or the length-
dependence of error-prone PolI. One disadvantage is its narrow mutation range (C to T
or G to A), but since AID-based methods have been used with success this may be
considered a secondary issue to be approached and optimised when the system is
developed.
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1.2.5. Aims of the project
Assessing the viability of the proposed system is the primary objective of this research,
and this effort may be broken up into several distinct stages:
• Defne a strategy for measuring mutation and use this as the basis of
experimental design.
• Show that the fusion protein retains the ability to a) effect transcription from
T7 promoters and b) cause mutation in a targeted manner, without imposing
such an untenable burden on the chassis – either mutagenic or metabolic – as
to destroy it
• Determine the effectiveness of the fusion at targeted mutation – to ensure it
incorporates a) a high enough rate of mutation that a useful sequence space
may be explored without being high enough to consistently degenerate the
target sequence faster than selection may be applied and b) an improvement in
targeting over expression of AID and T7 in an unfused conformation
• Demonstrate a practical application of the system – to mutate a chosen target
in a useful way, by diversifcation of a signaling molecule.
The genetic circuits used in the project are to be constructed using Synthetic Biology
techniques, with parts and devices kept compatible with Synthetic Biology standards.
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2. Constructing a system for in vivo directed 
evolution
2.1.1. Aims
Construction and testing of the device with an eye toward quantitatively estimating the
mutation rate of the system may be subject to experimental considerations or
constraints. Prior to beginning any experimental attempts to characterise the
mutational efciency of the device, a strategy must be defned for that characterisation.
From there, the experimental design constraints which must be adhered to can be
specifed.
The next fundamental aim is the construction of the device and any variants thereof,
which may be required to determine and rule out obfuscating factors contributing to an
observed mutation rate, such as background. Along with these device plasmids, target
sequences must be selected and placed behind PT7 in an appropriate context. The
devices and targets required for construction wil depend on the experimental strategy
informed by the method to be used for measuring mutation rate.
These constructs must be tested to ensure basic functionality – in the case of the fusion
protein, to ensure that both moieties retain function when fused.
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2.2. Experimental strategy
Assessing mutation rate may be done in a number of ways which fal broadly into two
classes: quantitative and qualitative/comparative methods. Qualitative methods
examine an increase above background, for instance, or compare two variants and rank
them without determining the defned mutation rate. Calculating the rate itself
quantitatively requires methods which are necessarily more complex and must adhere
to strict parameters.
2.2.1. Rifampicin reversion 
One widely-used method for comparative mutation rate experiments is rifampicin
reversion. Rifampicin is an antibiotic which interferes with native bacterial RNA
polymerases; it binds to the beta subunit of the RNAP and blocks transcription
initiation, preventing transcription of proteins and leading to the death of the cel
(Wehrli 1971). There are several possible point mutations that can occur in the
sequence encoding the RNAP which can result in amino acid changes but wil not alter
the function of the polymerase (Jin 1988). As such, they confer no reduction in ftness,
but they do prevent the binding of rifampicin and render the cel resistant to its effects.
These mutations may occur spontaneously (thus rifampicin is used therapeuticaly only
in concert with other antibiotics (Tupin 2010)) but do not represent the wild type.
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Culturing cels in the presence or absence of a putative mutator, and then exposing the
cultures to rifampicin (by plating on antibiotic-supplemented media for example) and
determining resistance reversion rates, alows mutagenic activity to be benchmarked.
Increased mutagenic activity wil result in increased mutations at one or more of the
points on the RNAP gene, resulting in increased frequency of reversion to resistance.
Importantly, excessive mutation of the RNAP gene wil result in cel death, eliminating
the problem of masking of successful reversion mutations by deleterious knockout ones.
This wil be examined in more detail in section 2.2.3.
Rifampicin reversion wil therefore be used to assess whether AID retains activity in
the fusion. Comparing the reversion rate of a strain transformed with the T7-AID
fusion protein to that of a negative and positive control (i.e. no AID and free AID
respectively), wil elucidate to what extent – if any – AID activity is inhibited by its
fusion to T7 RNAP. It is worth noting here that rifampicin does not interact with the
T7 RNA polymerase, as it lacks the structural motifs required (Kuderova 1999). 
2.2.2. Controls required for assessing targeted mutation 
For the mutator protein, however, the general increase in the mutagenic phenotype of
the cel is only part of the story. The rate of mutation of the target should exceed the
background increase, and it is this comparison that is important in determining the
35
efciency of the system as a whole. The conventional approach to the assessment of the
level of mutagenesis displayed by targeted directed evolution systems relies simply on
the sequencing of a large number of target DNA molecules post-mutation, and
comparison of the rate of mutation in those sequences to the native background. This
approach must be adapted for the assessment of the fusion protein, however, as it may
not be a strictly targeted system.
Unlike, for example, the modifed PolI method developed by Camps et al (2003) in
which mutations must fal within a specifc range after the origin of replication on a
plasmid; or MAGE where al mutation is confned to those areas targeted by diversifed
oligonucleotides, the T7-AID fusion's mutagenic activity may not be strictly
constrained to areas under the control of PT7. Since each mutator molecule wil not be
bound to and transcribing DNA at al times, they wil cause mutation at non-target
sites – the fusion effectively increases the background mutation rate of the cel. An
estimate of the rate of mutation which is only based on examining the sequence of the
target DNA 'before and after' exposure to the fusion protein wil therefore not be able
to be attributed to a targeted mutation effect without frst ruling out an enhanced
background mutation rate as being the cause.
Should AID be confrmed to have retained function in the fusion, the next step toward
assessing its viability as a directed evolution platform wil be to culture it with a target
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under PT7. In this case a comparison wil stil need to be made against free AID and
background mutation of the target, with an important additional consideration –
transcription-induced mutation. 
Double-stranded DNA (dsDNA) undergoes spontaneous deamination at a rate up to
140 fold lower than single-stranded DNA (ssDNA), and the rate of such deamination of
a stretch of DNA increases proportionaly with the amount of time that DNA is in a
single-stranded state (Lindahl 1974; Frederico 1990; Beletski 2000). When DNA
undergoes transcription, the separation of the strands exposes them to increased
mutation, and a higher rate of transcription means the DNA is separated more often.
Genes behind PT7, as a result of T7 RNAP's high activity, show a rate of spontaneous
deamination (C to U) which is up to 5 times higher than background levels (Beletski
2000).
This effect must be controled for – the negative and free AID controls must include a
T7 RNAP gene to ensure that any increase in targeted mutation over background is
not due simply to increased transcription by T7 RNAP. Thus the controls required –
alongside the fusion protein – were determined to be T7 RNAP alone and T7 RNAP
with AID unfused, both on otherwise-identical plasmids to the fusion protein.
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2.2.3. Masking as a consideration in gain of function assays
In the ideal case a gain of function assay would be used when determining the rate of
mutation at a target. This would typicaly be a reversion to resistance assay, as they
alow screening by plating on the appropriate antibiotic; this automaticaly eliminates
failures and leaves only successful revertants for scoring. Reversion to kanamycin
resistance using a kanS target is the standard gain of function assay, used commonly in
the literature (Sohail 2003;  Ramiro 2000). When a gain of function approach is applied
to the analysis of a mutator with a mutation bias – i.e. a targeted system – however,
one must account for a parameter that is otherwise safely ignored; masking of
successful revertants by knockout. If a given DNA sequence contains one base pair that
has been deliberately mutated to disrupt function, reversion of which wil restore that
function, it may also include one or more base pairs (or a combination of several) which
wil eliminate that function – even given successful reversion of the original mutation.
Figure 4 shows the effect of masking given one base that wil restore function if
mutated and one base which wil destroy it in a putative target; additional deleterious
mutation sites serve to shift the curve as shown in fgure 5.
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Figure 4: Masking effect of gene knockout, given one reversion and one knockout base
Demonstration of the masking effect introduced when a gain of function mutation may
be 'overridden' by a separate knockout mutation. In this graph, a synthetic sequence is
assumed to have one site each where a mutation event wil restore function and knock
it out, with knock out 'trumping' reversion. 
Determination of the number of sequences avoiding mutation at either site WT is the
product of the chance the mutator with efcacy e (ranging from 0, never mutates a
target, to 1, mutates every target) wil miss both the knockout site (number of knockout
sites k) and the reversion site (number of reversion sites r) so 
WT = (1 – e)k ∗ (1 – e)r
or  = (1 – e)(k + r)        
Determination of the number of knockouts K is by subtraction from the total, 1, of the
cases where al k knockout points are missed so 
K = 1 – (1 – e)k
The number of sequences successfuly reverting to function R can be determined by
subtraction of the above cases from the total, 1, or may be derived from the chance for
the mutator efcacy e to miss k knockout points and hit one of r reversion points so 
R = (1 – e)k ∗ (1 – (1 – e)r)
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Figure 5: Effect of number of knockout bases on reversion frequency
Demonstration of the masking effect introduced when a gain of function mutation may
be 'over-ridden' by a separate knockout mutation. In this graph, a synthetic sequence is
assumed to have one site where a mutation event wil restore function – plots for the
frequency distribution for different efcacies of mutator are given for a range of
possible numbers of knockout points (knock out 'trumps' reversion). 
So we can see that while with one possible knockout point, masking only becomes a
problem when mutator efcacy passes say 0.4, more knockout points causes masking to
come into play earlier and with more drastic effect. In a realistic scenario, the number
of knockout points in an assay is not only likely to be greater than the number of
reversion points, but is likely to be an unknown parameter and therefore not able to be
corrected for.
Masking may be safely left out of analysis only at very low levels of mutator efcacy;
this is the case in almost al scenarios in nature, as such an effective mutator would be
toxic to a cel, but targeted mutation rate may outstrip background to such a degree.
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With imperfect knowledge of both the efcacy of mutation and targeting of the fusion,
as wel as of the number of bases in the target which could eliminate function if
mutated, a reliable assessment of mutation rate cannot be derived purely from a
reversion to function assay.
For non-targeted systems, this is not a consideration. The reasoning behind this
assumption is that any global mutator with a high enough rate to fal prey to
disruption by the masking effect would be so effective as to be lethal to the cel. When
considering a targeted system, however, the rate of background mutation may be low
enough to endure while the rate of mutation at the target is high enough to skew data.
It is therefore necessary to determine what proportion of putative revertants would also
incur a knockout mutation. This may be done by performing a loss of function assay; if,
post culture and screening, half the targets have lost function (for example), then in a
gain of function test the true number would be double the number indicated by scoring
revertants.
While gain of function assays are best performed using antibiotic-based targets and
selection procedures, the same is not true for loss of function assays. Thus, while kanS is
generaly used in this context, there is no corresponding loss of function assay to alow
the analysis of masking. Instead, a pair of targets were designed – the GFP/XFP pair,
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a functional and knockout version of a fuorescent protein which differ by one base (a T
to C change from GFP to XFP – meaning AID can revert function by inficting C to U
deamination at that base). The data produced from these assays can then be analysed
to determine the efcacy of targeted mutation by T7-AID. 
2.2.4. Fluctuation analysis
For this project, fuctuation analysis was considered the most suitable method for
determining mutation rate (Foster 2006; Rosche 2000). In brief, the method consists of
calculating the number of mutation events, referred to as m, which most accurately
describes the distribution of the number of mutants observed across paralel cultures.
Counting the number of mutants alone wil not give an accurate measurement of the
number of mutation events in a bacterial host, as a single event wil be repeatedly
duplicated during the process of cel replication. The earlier the mutation event occurs,
the greater the effect wil be on the fnal number of mutants observed. Therefore,
comparing the distribution pattern of different cultures is a more accurate method to
determine m and remove the infuence of this effect.
After the seminal work by Luria and Delbruck (1943) frst described the distribution of
mutants in a population given that new mutants arise both spontaneously and by
division of pre-existing mutants, Lea and Coulson (1949) created the frst model to
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represent this distribution mathematicaly. Since then, a number of different methods
have emerged for calculating m from the observed distribution, such as the P0 method,
Lea-Coulson's method of the median, or the maximal likelihood method. A thorough
review of the advantages and disadvantages of each available method can be found in
Rosche and Foster (2000). 
The key point to remember when choosing which one to use for fuctuation analysis is
that each of these methods is suitable only for a certain range of m. Therefore, it is
necessary to have a rough estimate of the m value before performing more detailed
analysis. This is a common mistake when fuctuation analysis is carried out; for
example, in Sohail et al (2003) the researchers aimed to determine m of a free AID
protein using a kanamycin reversion to resistance assay. They chose Lea and Coulson’s
method of the median to analyse their data, which is valid when m is in the range of 4
to 15 (corresponding to a median number of mutants between 10 and 60) (Rosche
2000). However, the lowest m value calculated in their research was 21 for a control
sample while the highest value when AID was expressed was multiple orders of
magnitude above the upper limit of 15. The authors estimated a 50-fold increase in
mutation over background, but a comparable study by Ramiro et al (2003) produced a
more conservative estimate of 20-fold, demonstrating the variability that may be
introduced by the selection of the mutation rate estimation technique. 
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Finaly, an additional consideration when using these analysis methods is that each one
makes specifc assumptions about the colection of data for analysis, which must be
replicated as closely as possible in the experimental conditions. One of the common
assumptions is that every mutant is observed. This makes reversion to resistance assays
particularly suitable for fuctuation analysis, as every revertant can be counted.
When m cannot be estimated beforehand (or when it is very high, e.g. greater than 15),
there are two methods that are considered most suitable to use. The frst is Ma-Sandri-
Sarkar (MSS) maximum likelihood (Sarkar 1992), a recursive method which generates
distributions for a range of different m values and compares this to the distribution of
the observed values until the m which produces the best ft is found. An advantage of
maximal likelihood methods is that al the available experimental data are included, as
opposed to methods such as the median. The second method which is suitable for high
or unknown m values is a Bayesian approach (Asteris 1996). The frst step is to express
what is previously known about m as a predetermined probability density function
(referred to as the prior pdf). Folowing Bayes’ theorem, the experimental data
(number of mutants in paralel cultures) can then be used to transform the prior pdf
into a posterior pdf. This newly-generated pdf wil therefore encompass information
from both prior knowledge and the most recent experimental results. 
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In the original work describing the Bayesian approach, Asteris and Sarkar (1996)
derived m from experimental data using both Bayesian methods and MSS maximal
likelihood. They demonstrate that the Bayesian approach is the most efcient at
estimating m compared to previously described methods, including MSS. It is even
possible to incorporate both methods, by using MSS maximal likelihood frst to
generate a prior pdf before carrying out the transformation. The main beneft of the
Bayesian approach is that it can be used to combine the results of multiple
experiments, by using the results from the analysis of one experiment as the prior pdf
for subsequent runs.
Either a Bayesian or MSS maximal likelihood approach was determined to be the most
suitable for analysis of the data in this project, due to their advantage of being able to
calculate m without the need for an accurate starting estimate of its value. 
2.2.5. Culture conditions
Regardless of the method used to perform fuctuation analysis, it is important to keep 
in mind that the system being studied must comply with a number of assumptions as 
described in the original Lea and Coulson model (1949) in order to provide meaningful 
results. These constraints can reasonably be met using a wel-designed protocol; the 
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exact experimental conditions chosen in this project to ensure the assumptions are 
fulfled are described in table 1. 
To ensure that the cel's repair machinery did not revert any mutation events arising
from action by AID – in line with the assumption of fuctuation analysis – it was
decided that al experiments would take place in a strain defcient in uracil DNA
glycosylase, the enzyme responsible for the frst step in the base excision repair
pathway responsible for repairing C to T deamination. A strain with the gene (ung)
encoding uracil DNA glycosylase knocked out was available in the laboratory, termed
BH156 (Lutsenko 1999). Ful genotype information is available in section 7.1.1, table 3.
In order to be able to determine m with reasonable precision – within 20% –  at least
20 distinct cultures are required (Rosche 2000). It was decided that each run would
consist of 24 paralel cultures to alow for possible failures, and each would be repeated
a minimum of 3 times. A co-transformation approach was taken with the target and
device on separate, compatible plasmids.
46
Requirement Adjustment
Number of seed cels negligible compared
to fnal cel count
Cultures to be grown to saturation, and
seeded with ~150 CFU.
Successful mutation does not impair ftness Target gene non-native and not vital
Negligible reversion of successful mutations
AID causes C to T mutations, cannot
revert T to C. ung- background favours
retention
Every reversion event is detected
Lethal selection is required, not actioned.
Sampling error must be taken into
account
Post selection, no new revertants appear No selection pressure toward revertants
Each mutation event is independent Not actionable
Table 1: Requirements for an accurate determination of m by fluctuation analysis, with
actions taken to atempt to satisfy them in the design of experiments
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2.3. Results
2.3.1. Construction of mutator protein
The mutator protein, comprising the AID-T7 fusion between a lac-inducible
promoter/ribosome binding site (RBS) pair and a terminator fanked by BioBrick prefx
and sufx sequences (Shetty 2008), was constructed prior to the start of this project. A
brief outline of the original construction is given here. 
Mammalian AID was codon-optimised, and the sequence sent for de novo gene
synthesis (by Geneart AG) along with an upstream BioBrick prefx sequence, lac-
inducible promoter PLac (part BBa_R0011 from the Registry of Standard Biological
Parts, parts.igem.org) & RBS32 (Registry part BBa_B0032) and a trailing sequence
comprising the frst half of the linker sequence used to fuse AID to T7 RNAP. The T7
RNAP gene, minus its start codon, was amplifed from the genome of E. coli
BL21(DE3), using primers designed to incorporate a restriction site (EcoRI) and the
latter half of the fusion linker sequence on the 5' end of the gene, and a double stop
codon folowed by a BioBrick sufx on the 3' end. The T7 RNAP sequence was PCR
purifed and cloned into a BioBrick vector, pSB1AK3 (henceforth abbreviated pA3)
containing the transcriptional terminator BBa_B0015 (Registry) via insertion before
that part. Folowing ligation and purifcation, the PLac-AID and T7 RNAP-terminator
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sections could thus be cloned together via restriction cloning at the shared SphI site in
the linker, creating the fusion (pA3:TA). The linker region used here for cloning
contains AgeI, SphI and NgoMIV sites. These alow modular extension of the linker by
restriction and ligation, in the event the fusion is discovered to lack AID activity;
adjusting the length of the linker may restore it in that case.
2.3.2. Construction of controls
The control devices, T7 RNAP alone and T7 RNAP with AID expressed separately,
were constructed by PCR.  Primers T7F/R were designed to linearise the fusion
plasmid minus the AID moiety, with the missing start codon being added to T7 RNAP
via addition to the forward primer. The two primers also included 15 bp homology with
each other on the 5' ends, alowing the InFusion assembly method to be used to re-
circularise and ligate the plasmid (pA3:T).
This technique was repeated to create an AID-alone variant of the plasmid using
analogous primers AIDF/R (adding a stop codon), and the two genes were then cloned
together using BioBrick methods to create the unfused control (pA3:T+A).
The control plasmids were sized folowing colony PCR with primers VF2 and VR, and
the correct sequence was confrmed by DNA sequencing.
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Figure 6: The device plasmids; the fusion protein and two controls, on a high-copy backbone 
Top: pA3:TA, the T7-AID fusion protein in pSB1AK3. The T7-AID insert is behind a lac-inducible
promoter (PLac) with a strong RBS (RBS32) and a pair of transcriptional terminators (XX) directly
flanking it. The insert is appended with the BioBrick prefix and sufx, containing EcoRI/XbaI and
SpeI/PstI restriction sites respectively. The backbone possesses kanamycin and ampicilin resistance
(KanR and AmpR respectively) and utilises a high-copy ColE1 origin of replication. 
Botom, left: pA3:T, T7 RNAP without AID in pSB1AK3. Botom, right: pA3:T+A, T7RNAP & AID
unfused, each behind their own PLac.
Figure 7: Agarose gel showing the products of a colony PCR
confirming successful construction of device plasmids
Lane 1, 1 kb DNA ladder; Lanes 2-4, T7RNAP, T7-AID and
T7&AID PCRs with VF2 and VR showing expected sizes.
5 kb
4 kb
3 kb
2 kb
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2.3.3. Construction of GFP and XFP targets
GFPmut3b, a mutant of the green fuorescence protein (GFP) from Aequorea victoria
engineered to alow faster folding and increased quantum yield, as wel as a tighter
excitation/emission spectrum (501/511 nm respectively), was used as the target
sequence (Cormack 1996, Andersen 1998). GFPmut3b behind PT7 was cloned from the
Registry plasmid pSB1A2 into pACYC-Duet (abbreviated pCD) and pSB4C5 (pC5),
using Biobrick methods (section 7.2.8). Briefy, genes were excised from their backbones
by either EcoRI/SpeI or XbaI/PstI double digest and inserted into vectors cut
EcoRI/XbaI or SpeI/PstI respectively. This concatenated the sequences, re-forming the
EcoRI/PstI site and forming a scar between the parts where XbaI/SpeI were ligated.
This produced plasmids pCD:PT7-GFP and pC5:PT7-GFP.
Site-directed mutagenesis was performed on the resultant plasmids, introducing a T to
C point mutation at base pair 196 (amino acid 66) of the mut3b gene; the resultant
amino acid change from Tyrosine to Histidine (Y66H) shifts emission from green
toward the blue end of the spectrum in wild type GFP (Heim 1994) but knocks out
fuorescence entirely in mut3b. This non-fuorescent variant was termed XFP, and both
GFP and XFP were tested for expected fuorescence profles by transformation into
BL21(DE3) after confrmation of successful construction by sequencing.
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Figure 8: Agarose gel showing the products
of a colony PCR confirming successful
construction of GFP target plasmids
Lane 1, 1 kb DNA ladder (NEB); Lanes
2-5, colony PCRs with VF2 and VR
showing expected size of GFPmut3b in
pSB4C5.
Figure 9: Agarose gel showing the products of
an analytical digest confirming successful
production of XFP by SDM
Lanes 1 & 6, 1 kb DNA ladder; Lanes 2-5,
XFP in pSB4C5 double-digested with EcoRI &
PstI showing expected sizes of both vector and
insert.
Figure 10: The target plasmids
Left: pCD:PT7-GFP, the PT7-GFP target in pACYC-Duet. The backbone possesses
chloramphenicol resistance (CamR) and utilises a medium-copy P15A origin of
replication. Right: pC5:PT7-GFP, the PT7-GFP target in low-copy pSB4C5 which also
contains chloramphenicol resistance but utilises a low-copy pSC101 origin of replication.
XFP targets are identical, with XFP replacing the GFP target producing pCD:PT7-XFP
and pC5:PT7-XFP.
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2.3.4. Confirmation of activity of devices
Activity of both the T7 RNA polymerase and the AID module within the chassis
needed to be confrmed before any attempt to utilise them for more complex
experiments. To this end, pCD:PT7-GFP was co-transformed into a non-DE3 strain
(GM31) along with pA3:T, pA3:TA and pA3:T+A device plasmids. These were then
plated and al exhibited glowing colonies, confrming T7 RNAP activity was maintained
post cloning and fusion. AID activity was assessed by using the rifampicin reversion
assay described earlier and detailed in section 7.6.1. Twenty platings were performed
over two separate runs of ten independent cultures each, and the results tabulated and
plotted as shown in fgure 11. 
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Figure 11: Rifampicin reversion assay
Device plasmids were tested for a mutagenic phenotype. 10 independent cultures were
assayed with 2 repeats. Standard error across al samples is shown.
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2.4. Discussion
2.4.1. Summary of strategy
Table 2 presents a summary of the experimental strategy that was devised based on the
considerations discussed above. This strategy informed the design and construction of
the devices, the choice of targets, and the experimental work-fow. 
Question Experiment
Does AID retain function in the fusion? Rifampicin reversion assay vs. background
Is that function inhibited in any way? Comparison to unfused AID
Does the fusion cause mutation of a target
gene?
Co-transformation of the fusion with a
target gene under T7
Can this be accounted for by transcription-
induced mutation?
Co-transformation of T7 RNAP without
AID with a target under T7
Can it be accounted for by non-targeted
AID activity?
Co-transformation of T7 RNAP and AID
unfused with a target under T7
Can repair be eliminated?
Al experiments to be performed in a
repair-defcient (ung-) chassis
Can m be assessed quantitatively? 'XFP' reversion assay wil alow this
Table 2: Experimental strategy; questions and the experiments designed to answer them
2.4.2. Construction
The requisite control devices (fgure 6) and target constructs (fgure 10) were
successfuly cloned into appropriate backbones, with al construction confrmed frst by
either colony PCR (fgures 7, 8) or analytical digest (fgure 9), then by gene
sequencing. The placement of the devices on high-copy plasmids should result in
saturation of transcription at PT7 – the targets being placed on low-copy plasmids
55
(pC5, ~5 copies per cel and pCD, 10-15 copies). Multiple backbones were used for the
target to alow potential optimisation of the mutagenesis protocol; higher copy numbers
could improve plasmid yields, with a lower copy number alowing more effective
screening.
2.4.3. AID retains functionality in the fusion
The cels containing a plasmid expressing AID (whether fused to T7 RNA polymerase
or separate from it) exhibited a higher background mutation rate than the cels
containing T7 RNAP alone, demonstrating that AID retained its mutagenic effect post
cloning and transformation into the chassis, and further, retained it apparently
uninhibited when fused to the T7 RNA polymerase (fgure 11). This demonstrates that
AID activity is comparable in the fused confguration to that of free AID, so any
increase in action on the target may be accounted for by a targeting effect. 
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3. Multi copy target analysis
3.1.1. Aims
Folowing the construction of the device and necessary control plasmids, the T7-AID
fusion protein is ready to be tested to determine its efcacy at targeted mutation. First,
it is necessary to develop an assay for accurate assessment of the targeting effect of
mutation. This assay should adhere as far as possible to the constraints required for
fuctuation analysis of the data, so that a quantitative measurement of the device's
activity can be determined.
3.1.2. Plasmid-based systems require segregation of targets
Gain of function assays may be carried out in plasmid-based systems, as successful
mutations wil cause a change in phenotype in the cel despite the possibility of it
retaining plasmids bearing the non-functional genotype. Loss of function assays,
however, require separation of plasmids prior to screening as successful knockout of
function in one plasmid wil not alter the phenotype – given a stable copy number of
plasmids in the cel.
Separation of plasmids post-culture is achieved via purifcation of the plasmids from
lysed cels (miniprep) and re-transformation. This also alows the opportunity for
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elimination of the device plasmids, which may cause mutation post-selection, by
transforming into a chassis expressing T7 RNA polymerase (i.e. a DE3 strain) and
selection only for the target plasmid antibiotic; in this case, chloramphenicol.
Assuming the square of the transformation efciency to describe the maximum
proportion of cels which may incorporate multiple plasmids, the vast majority of
successful transformants wil begin with a single plasmid and therefore represent a
single sample of the entire plasmid population. Any cels which take up a device
plasmid also should incur a reduction in ftness, there being no beneft to retaining it in
an environment without selection for it and some detriment to the cel (increased
burden, and expression of a mutagenic protein). This should assist a reduction in the
number of post-selection mutations.
After assessment of manual solutions to mass plasmid purifcation and transformation
techniques, it was determined that the protocol was amenable to adaptation for use on
a liquid handling robotic platform; al the stages of the protocol after growth to
saturation, from inoculation through culturing to plasmid purifcation and
transformation, were theoreticaly achievable on a liquid handler.
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3.2. Results
3.2.1. Automation
A script was written and optimised to alow the purifcation and transformation of
plasmids from cel culture into fresh cels entirely on the liquid handling platform. The
script is included in appendix 9.2. These cels were then plated manualy, and colonies
scored after overnight growth.
This high-throughput work-fow alowed a ful run of 288 cultures, comprising the 4
device plasmids incorporating pA3:TA with the three controls (pA3:T, pA3:T+A and
empty) and pCD:PT7-GFP, to be processed over two days. The data from this run is
shown in fgure 12, with raw data in appendix 9.1.1. 
52 cultures did not grow up folowing inoculation, yielded too little DNA to transform
or showed zero colonies post transformation. In addition, one entire repeat of the T7
RNAP control failed to grow up in culture. However, the automated protocol was
otherwise successful, with the platform purifying and transforming the DNA over the
course of the morning and afternoon. Yields of up to 1 µg were realised after
substantial optimisation and adaptation of the protocol. Plating was carried out in the
evening. Colonies were observed on most plates, with around 20% showing no growth,
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after 16 hours incubation. The plates were moved to a 4°C environment to alow
maturation of GFP while minimising overgrowth of the colonies.
The number of colonies was lower than expected (fgure 12), which was traced to a
greater reduction in efciency of the miniprep procedure than had been alowed for. Of
the 3 repeated runs with a control plasmid and the three device plasmids, rarely did
the desired 20 cultures translate to countable colonies, and thus the data could not be
used to determine mutation rate (Rosche 2000). 
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Figure 12: Colony counts from automated plasmid isolation and transformation
Each cluster of three repeats relates to a different experimental condition – left, no
device plasmid transformed; second left, T7 RNAP alone transformed; second right,
T7-AID fusion and right, T7 & AID unfused. Dark blue bars represent the number of
colonies across platings from al cultures (left-hand axis) and light blue bars the
percentage of those colonies exhibiting zero fluorescence after transformation into
BL21-DE3 (right-hand axis).
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The automated protocol was adapted, with the concentration of DNA used to
transform being increased in an attempt to improve colony count, but due to a
combination of factors including inefciency of the mini-prep protocol with low-copy
pC5 targets, the second run was performed using the alkaline lysis procedure with spin
columns (EZNA Silica Column Miniprep Kit, Omega Biotech). The robot was used for
pipetting and transformations. This gave acceptable plasmid yields (1.5-4 ug) and
colony numbers when transformed into BL21 cels; almost al plates harboured a
substantial number of colonies (an average of ~660 per plate), and were moved to a 4°C
environment for 48 hours to alow GFP maturation while minimising overgrowth.
Plates were imaged under UV light and colony numbers were scored using colony-
counting software. Differentiation of fuorescent vs. non fuorescent colonies was applied
via manual level adjustment and curation of each image to ensure accuracy.
The data from these runs for the fused and unfused plasmids are shown in fgure 13
(the raw data are tabulated in appendix 9.1.2); the T7 RNAP and cels lacking a device
plasmid both showed zero loss of function across al cultures and are not included.
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Figure 13: Colony counts from semi-automated plasmid isolation and transformation
Each cluster of three repeats relates to a different experimental condition – left, T7-
AID fusion and right, T7 & AID unfused. Dark blue bars represent the number of
colonies across platings from al cultures (left-hand axis) and light blue bars the
percentage of those colonies exhibiting zero fluorescence after transformation into
BL21-DE3 (right-hand axis).
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3.3. Discussion
3.3.1. Adaptation to automation
Human error and variability of technique were found to introduce high variability to
the yields of DNA acquired during the required segregation of plasmid step. This, as
wel as the repetitive and time-intensive nature of the process, led to the migration of
the work-fow to an automated platform.
Three kits were available for plasmid purifcation with the liquid handler – two
magnetic bead-based (Promega's Wizard MagneSil Plasmid Purifcation System and
Qiagen's MagAttract 96 Miniprep Core Kit) and a column-based (Qiagen's Qiaprep 96
Turbo Miniprep Kit) solution. The column-based kit was ruled out early, as the
vacuum system used in place of a centrifuge on the robotic platform suffered from
uneven distribution of pressure across the wels in the plates, which would impact the
quality and quantity of DNA purifed and introduce unwanted variation in yields.
The other two kits were tested manualy, to determine expected yields. DNA
concentration was assessed by gel electrophoresis and spectroscopy, and confrmed using
transformation and plating with colony counting compared to a control. The MagneSil
kit yielded very pure DNA, but at lower concentration; the number of colonies post-
transformation was below what was required. The MagAttract kit produced acceptable
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yields even when reagent volumes were halved, alowing a more cost-efcient protocol.
As mentioned, on average ~1 µg yields were reached with the medium-copy plasmid
pCD. However, it was less suitable for the low-copy pC5, and thus manual involvement
was stil required in this instance. 
Overal, the use of the liquid handler streamlined an otherwise labour-intensive work-
fow, which had been shown to impact negatively on the turnover of the procedure to
data. It also removed the possibility of mistakes arising from human error from most of
the complex, and otherwise standardised (i.e. kits and standard laboratory procedures)
portions of the protocol.
3.3.2. Data quality and limitations
As described in Chapter 2, it was decided that to decouple untargeted and targeted
mutation by the fusion, an unfused T7-AID device was needed as a control to
determine if targeted mutation by the T7-AID fusion was higher than background
mutation and a T7 alone device for determination of transcription-induced mutation
rates. The data produced by the automated run, shown in fgure 12, show that some
loss of function colonies were seen in those platings derived from both the AID-
containing devices and the negative/T7 RNAP controls. The inconsistencies between
the triplicate runs prevents deeper analysis of the data however – while the unfused T7
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AID construct demonstrated a substantial percentage of knockout colonies for runs 2
and 3, both above the more consistent level of the fusion, run 1 showed a far lower rate.
The T7 alone control, shown in fgure 11 to have a negligible mutation rate, showed a
loss of function percentage consistent with this in run 1. In run 2, however, it showed a
rate above that of al three runs for the fusion – the same pattern was seen in the pure
negative control, with run 3 showing some loss and 1 and 2 showing none.
It must be noted that these data cannot lead to frm conclusions due to oversampling
as a result of the limited successful transition from culture to colonies (see appendix
9.1.1. for the data tables used to produce fgure 12). For this reason, a second run was
attempted.
The second run used manual purifcation of plasmids. While al cultures successfuly
translated to scorable transformations, there was stil a concerning level of inter-repeat
variability for the device plasmids containing AID. The negative control and T7 RNAP
alone showed zero loss of fuorescence across al plates, in line with expectations and
appearing to show that transcription-induced mutation alone was negligible. The
devices containing AID showed a consistent level of mutation for 5 out of the 6
combined runs (between 0-0.5% loss of fuorescent colonies). The exception was run 1 of
the unfused mutator protein; loss of fuorescence was observed in around 19% of
colonies.
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This variability in assessment of the rate of knockout of GFP means that an estimate
of the masking rate cannot be made with confdence from these data; as discussed in
section 2.2.3, this is the required parameter that the loss of function assays aimed to
evaluate.
An interesting development observed during scoring of these runs is that, upon close
inspection, more of the fused colonies appeared to have lost function when in fact they
were weakly fuorescent. The counts in fgure 12 are correct, with loss of function/GFP-
ve data defned as zero fuorescence, but this suggests that while the fusion is less
effective at completely disrupting fuorescence it may be causing knock-down of the
output by more sparse disruption of the gene sequence. Responsibility for this pattern
lying with some other factor, and the fusion causing no mutation, may be ruled out by
the absence of any such pattern in the T7 control set.
An alternative explanation could be co-transformation of knockout plasmids with un-
mutated plasmids – or unmutated plasmids with device plasmids – causing either an
effective reduction in copy number of the wildtype GFP gene or continued mutation
post selection and accordingly decreased fuorescence; the assumption that such
multiple transformation events were unlikely (co-transformation probability reasonably
estimated as the square root of the transformation efciency) is at the heart of the
miniprep/re-transformation procedure. Examining the literature to determine the
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validity of this assumption revealed concerning data – Hanahan (1983) shows that co-
transformation of compatible plasmids occurred in 70-90% of the transformants in a
reaction where cels were saturated with DNA. He posits that rather than al cels in an
aliquot having equal amenity to transformation, a smaler subset of those cels are
hyper-competent; thus transformation efciency remains the same but co-
transformation is much more likely than previously assumed.
With no selection for the device plasmid, and competition between any distinct target
plasmid co-transformations (having the same origin of replication) leading to
segregation, it could be expected that by colony growth the cels wil have lost the
device and only contain one target plasmid.  However, the time for this to occur is an
unknown variable, and the results may be interpreted differently based on that.
If we assume co-transformation is a common event, with the number of plasmids being
taken up by a cel p and the proportion of plasmids with the maskable genotype (in
this case, loss of fuorescence) m, we can see that the proportion of colonies which wil
show that phenotype x can be found by:
x = mp
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This is an oversimplifcation, as it ignores post-transformational segregation, and is also
the worst-case scenario as it assumes ful DNA saturation which may not have been the
case as it was in Hanahan's experiments.
Even with those caveats, however, it is clear that because the single plasmid per
transformation event assumption is incorrect, the number of colonies counted with a
non-fuorescent phenotype wil be lower than the number of colonies transformed with a
plasmid of the corresponding phenotype on that plate. For this reason, it was decided
that further plasmid-based runs were not to be attempted, and the targets were to be
adapted to a single-copy assay.
It is worth noting here that the main difculties – namely efcient scale-up of plasmid
segregation without loss of quality, and the need to double the sample size (as a result
of the need to examine loss- and gain-of function rates) to account for masking – are
not issues which would affect a plasmid-based application of the system toward directed
evolution. Once even the approximate mutation efciency of the device is known,
masking can be accounted for or disregarded, and the need to segregate plasmids pre-
selection would be eliminated in gain-of function experiments.
69
4. Single copy target analysis
4.1.1. Aims
The issues encountered during the plasmid-based testing stages, and detailed in chapter
3, forced a necessary change in direction for the project's approach. Further attempts
to optimise the multi-copy system for assessing the mutation rate of the system were
deemed intractable, as the previous heavy optimisation and automation of much of the
process stil resulted in a rate of data generation that was not sustainable, with any
further improvements providing only diminishing returns.
With the above considerations in mind, the project was refocused toward a single-copy
testing strategy. This opened up new avenues for the screening of constructs, namely by
the use of fow cytometry to quantitate GFP fuorescence on a single-cel basis. The
high-throughput nature of fow cytometry also alows many more distinct cels to be
examined than may be reasonably seen by plating and scoring colonies.
The frst aim for this chapter, therefore, is to integrate a target onto the host cel
genome. This is to be folowed by high-throughput analysis using fow cytometry, to
examine large cel populations quickly and efciently. Lastly, target sequences are to be
examined directly via sequencing to determine mutation efcacy and any relevant
patterns.
70
4.2. Results
4.2.1. Genome integration of targets for single-copy analysis
Genome integration used the CRIM (for Conditional Replication, Integration and
Modular) plasmid system (Haldimann 2001). A variety of CRIM plasmid pairs exist.
For the purposes of this project integration plasmid pAH153 and helper plasmid
pAH123 were selected, for two reasons; frst, they used the Φ-80 integration site,
demonstrated to possess a high efciency of integration by the authors and second,
pAH153 relied upon a gentamycin resistance marker on the integration construct. This
antibiotic was not used on any of the other plasmids in the mutator system, and would
facilitate cloning and screening by alowing elimination of carry-over as it was distinct
from that in the original construct (chloramphenicol).
The target genes – GFP and XFP – were separately cloned into the CRIM integration
plasmid using CPEC (see Methods section 7.2.7, primers CRIM_Gene_F/R &
CRIM_153_F/R) to produce pCRIM:GFP & pCRIM:XFP (fgure 14). Biobrick
fanking sequences were included, to alow for future cloning by that method should it
be required. This also has the beneft of enabling more consistent CPEC/Gibson (see
Methods section 7.2.6) cloning, as previously the insertion site was directly fanked by
transcriptional terminators.
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Upon confrmation of correct construction via sequencing, the plasmids were co-
transformed into competent BH156 cels. Successful integration was achieved folowing
the CRIM procedure. This was confrmed (see fgure 15) by the 4-way PCR described
by Haldimann & Wanner (2001), with some primer sequence alteration to account for
the altered fanking sequences (primers CRIM_1/2 & 4 were used as described by
Haldimann et al, but CRIM_P3 required modifcation to account for sequence
differences at its site – this primer is CRIM_T3). A positive result, with a single
integration, produces two bands; a negative result, one band and a multiple insertion
event, three. Figure 15 shows that both XFP and GFP targets were integrated
successfuly. Successful integration was further confrmed by sequencing of a colony
PCR encompassing the entire integration site.
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Figure 15: Agarose gel showing the products of an analytical PCR demonstrating
successful integration of GFP/XFP
Lane 6, 1 kb DNA ladder; Lanes 1 & 2, colony PCRs of strains with GFP (lane 1) and
XFP (lane 2) integrated into the genome by CRIM; Lane 4, positive control; Lane 5,
negative control.
Figure 14: GFP target cloned into pAH153 for integration onto the E. coli genome
Plasmid pCRIM:GFP wil alow genome integration of the GFP target via the CRIM
integration system. pCRIM:XFP is identical, with GFP replaced by XFP.
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Curing of the helper plasmid pAH123 – which carries an ampicilin resistance gene,
making it incompatible with the device plasmids – was effected by repeated rounds of
re-streaking and positive/negative selection, and was confrmed by colony PCR against
helper plasmid DNA compared to controls.
The strains with integrated targets were termed BH156-GFP and BH156-XFP. These
were made competent, ready for transformation by the device plasmids; colonies were
picked post-transformation, and grown up for glycerol stock as expeditiously as possible
to minimise mutation in this period. These glycerol stocks were then used as seed
cultures for the mutation runs, which were otherwise carried out folowing the protocol
for the plasmid-based target assay (minus the unnecessary target antibiotic).
These runs produced cultures that were diluted in double-distiled water (ddH2O) for
analysis on a fow cytometer. 
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4.2.2. Analysis of mutation of single-copy targets by flow
cytometry
Early culture runs, folowing the procedure for the plasmid-based assays, produced
several mililitres of culture – since only 20-50 µl are needed per sample for analysis by
fow cytometry, it was determined that smaler culture volumes could be used. This
alowed optimisation of the protocol, and specifcaly, alowed adaptation of the culture
step to a semi-automated procedure.
Adapting the protocols previously designed for the liquid handler to culture growth was
relatively trivial. A second liquid handling platform, of the same make and model,
included a plate incubator which alowed temperature and shaking control of 96/384-
wel micro-titre plates integrated into the platform.
This alowed time-course experiments to take place; the automated platform re-diluting
the cultures throughout the day and overnight and saving samples on a cooled position
and diluted in ddH2O to stop further growth.
A negative control, of BH156-GFP cels without a device plasmid – and therefore
lacking the T7 RNA polymerase required to transcribe GFP from the genome – was
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used to calibrate the machine for cel size and complexity, and to determine a suitable
dilution coefcient for the samples which avoided multiple-cel events.
A positive control, pA3:T, was transformed into the BH156-GFP strain. This was used
to calibrate the machine for sensitivity; the gain of the detector was increased to alow
both fuly-fuorescent cels and those with no fuorescence at al to be visible as distinct
peaks. Standard settings cluster non-fuorescent cels on the Y-axis, giving misleading
data, and an accurate distinction of fuorescent and non-fuorescent cels is a vital
requirement of the assay.
With the machine calibrated suitably, the settings were saved and used for every run
beyond the frst to ensure consistency of data and alow inter-run comparisons.
Flow cytometry results for loss of function assays, with device plasmids transformed
into BH156-GFP, are shown in fgure 16. The unfused mutator causes drastic loss of
fuorescence when compared to the fusion, which shows a less marked effect. Both show
reduction in fuorescence relative to the positive control, T7 RNAP alone, which
consistently showed no loss of fuorescence over the course of these experiments. Figure
17 shows data from a longer run with the unfused device plasmid; four 8-hour
timepoints were assayed. Data from both manual and automated runs were in
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agreement as to the relative effects and effectiveness of the device strains, and a
mixture of both approaches produced the data shown in fgures 16 & 17.
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Figure 16: Time-course flow cytometry data showing loss of function profiles for the
device plasmids
Each row represents a repeat with an independent culture. From left to right are
histograms representing cel counts for a negative control (pUC19) in grey, T7 alone in
red, TA fusion in green, and T+A unfused in blue. The darker peak was sampled at 8 h
post inoculation; the lighter peak at 24 h after 2 cycles of re-dilution and growth for 8 h
in fresh media. Fluorescence is shown increasing logarithmicaly from left to right on
the x-axis.
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Figure 17: Time-course flow cytometry data showing loss of function profile over 32
hours for the unfused device plasmid
Top left to botom right: Four 8 hour timepoints were sampled, and the individual
graphs combined to highlight the progressive accumulation of loss of function mutants
over time.
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4.2.3. Sequencing of genome-integrated GFP target
A number of colonies representing each of a stable fuorescent and knock-out phenotype
were selected for sequencing from both the fusion and unfused device plates. The T7
RNAP positive control plates did not show any knock-out colonies, so only fuorescent
colonies were selected. Elimination of short or low-quality reads left a set size of ten
sequences for the control and the fusion fuorescent and non-fuorescent categories, and
eight and seven acceptable reads for the unfused fuorescent and nonfuorescent
categories, respectively.
These were aligned to the DNA sequence of the GFP construct as verifed during
construction using the inbuilt alignment feature in ApE (alignment used the
Needleman-Wunsch algorithm (Needleman 1970), requiring cropping of sequences and
reference to similar lengths, block size 10); basecals from the sequencing company were
initialy used to seed the alignment. Post-alignment, each putative
mismatch/insertion/deletion mutation event was examined and located within the
corresponding sequencing trace fle. Erroneous basecals were corrected where obvious;
where signifcant doubt existed as to the correct cal, basecals were accepted. Appendix
9.3.2 shows sections of the relevant trace fles corresponding to each mutation event. Al
recorded mutation events were observed in sequences amplifed from cultures containing
the T7-AID fusion device; T7 RNAP alone and T7 RNAP and AID unfused culture
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sequences al corresponded to the original GFPmut3b sequence, for both fuorescent
and non-fuorescent colonies.
Figure 18 shows the sequence of PT7-RBS34-GFPmut3b, with highlighted letters
indicating positions where at least one mutation event was recorded. C to T or G to A
mutations make up the vast majority of recorded events, representing 16 of the 19
mutations. Note one position had 2 distinct mutation events, and a second position, 4 –
this is represented more clearly in fgure 19, which maps the distribution to the amino
acid sequence of the GFP target. Ful details of the mutation events are in table 6 in
appendix 9.3.1.
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Figure 18: Mutations in the GFPmut3b sequence induced by exposure to the mutator
protein
Uppercase; open reading frame, start codon in green. Holow leters indicate mutations
not resulting in an amino acid change; black, those that did. Underlining indicates C to
T or G to A mutations, i.e. those that may have been cause by AID action. Italics are
used where more than one event was observed at the same point across multiple
samples.
tagagtaatacgactcactatagggagatactagagattaaagagga
gaaatactagATGCGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCC
CAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCT
GTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCT
TAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACAC
TTGTCACTACTTTCGGTTATGGTGTTCAATGCTTTGCGAGATACCCA
GATCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGG
TTATGTACAGGAAAGAACTATATTTTTCAAAGATGACGGGAACTACA
AGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATAGA
ATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGG
ACACAAATTGGAATACAACTATAACTCACACAATGTATACATCATGG
CAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACAC
AACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAA
TACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACC
TGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGAC
CACATGGTCCTTCTTGAGTTTGTAACAGCTGCTGGGATTACACATGG
CATGGATGAACTATACAAATAAtaatactaga
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Figure 19: Map of observed mutation events along the GFPmut3b target gene
The amino acid sequence of GFPmut3b runs clockwise from the top; intersections with
lines indicate a mutation event was detected in at least one sample at that point. Red
lines indicate mutations not resulting in an amino acid change; black, those that did.
Solid lines indicate C to T or G to A mutations, dashed indicate other events. Thicker
lines are used where more than one event was observed at the same point across
multiple samples.
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4.3. Discussion
4.3.1. Production of strains with genome-integrated targets
To alow use of the system on a single target, integration of that target onto the
genome of the chassis strain was required. This would guarantee a single copy is present
at al times (excepting during replication events, an exception which may safely be
ignored) and ensures stability of that target in the host. The device and targets used
above were stil viable for use in a genome-based system, requiring only that the targets
be adapted into a form amenable for integration.
It was decided that the CRIM system developed by Haldimann & Wanner (2001) was
the easiest and most ftting method to use. A plasmid-based system, it had already
been used in a synthetic biology context (Anderson 2010) and involved only routine
laboratory protocols – cloning, plasmid propagation, transformation and curing, al of
which had established and optimised work-fows in the lab.
The CRIM protocol relies on co-transformation of the target construct plus a resistance
marker on a plasmid which is unable to replicate in normal bacterial strains, with a
helper plasmid that causes recombination of sequences fanking the target with specifc
sites on the genome of E. coli. Thus, only by successful integration wil the cels exhibit
resistance to the chosen antibiotic. The helper plasmid contains a heat-sensitive origin
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of replication, and may be cured post-transformation by an elevated temperature
incubation and negative selection for its antibiotic resistance. 
In this way, the GFP and XFP targets were successfuly integrated into BH156 at
single copy by cloning them into the integration plasmid (propagating the resulting
construct in a pir+ strain which alows replication of the plasmid) and carrying out the
co-transformation and selection/curing procedure. The resulting strains were caled
BH156-GFP and BH156-XFP. 
Transformation of device plasmids into these strains, and the subsequent culturing
procedure, folowed the protocols developed for the multi-copy analysis work-fow.
4.3.2. Flow cytometry
The fow cytometer alows a population to be assessed with single-cel precision in a
much more reliable way than via e.g. dilution and plating, with the added advantages
of far greater sample sizes and elimination of possible mutations during the post-culture
incubation phase. Since the fuorescence detector matches the emission spectra, this
alowed the use of the GFP constructs without alteration – and by quickly examining
tens to hundreds of thousands of individual cels, patterns in mutation can be detected
easily by looking for distributions of cels within sub-populations defned by their
fuorescent characteristics.
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The positive control run with T7 RNAP alone used to calibrate the cytometer showed
effectively zero loss of fuorescence after a 16 hour incubation, and this pattern was
replicated in al later runs with the T7 RNAP device plasmid. This was consistent with
the preliminary data from the plasmid-based plate assays and demonstrated that, while
transcription-induced mutation is a recognised effect (Beletski 1996; Francino 1996),
and T7 RNAP transcribes at an elevated rate (with a single-copy target, we expect
almost continuous transcription along much of the gene), any resulting knockouts
arising from said mutation are negligible within the context of the overal population
and thus that any contribution to knockout populations in the runs using other devices
may be safely ignored.
The plasmids incorporating an AID moiety consistently conferred a mutator phenotype,
as evidenced by a drastic increase in the number of knockouts seen within the
populations examined on the fow cytometer. The fusion showed a smaler peak of non-
fuorescent cels after 24 hours culture (3 repeated dilution/growth cycles), with most
cels retaining the fuorescent phenotype; this was routinely mirrored in the unfused
device plasmid samples, with most cels having lost fuorescence and a smaler
population retaining it post culture. After 24 hours approximately 50% of cels cultured
with the unfused device had lost fuorescence (fgures 16 and 17).
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These data suggested that the free AID device was the more profcient at causing
mutation, as it was consistently effective at knocking out fuorescence in the genome-
integrated GFP target. To elucidate further the exact rates and distributions of
mutation events, examination of the sequence of the genomic target post-culture was
required.
4.3.3. Sequencing
Post culture and analysis, remaining volumes of samples were plated. This alowed
colonies to be selected for colony PCR amplifcation of the GFP gene from the genome;
these were then purifed and sent for sequencing to alow direct analysis of the
mutation profle of a number of colonies – both fuorescent and non-fuorescent – for
each device plasmid. This work is ongoing, but data colected so far are examined
below along with analysis and discussion of how they might inform future work on the
project.
Every confrmed mutation event (displayed in fgure 18) occurred in colonies containing
the fusion device plasmid. This was an unexpected result; the fow cytometry data
demonstrated clearly that the unfused T7 and AID protein expression strategy was
more effective at knocking out fuorescence more quickly. This does not seem to be a
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result of more mutation within the actual GFP gene, however, given the lack of
mutation events within the target confrmed by sequencing.
This distribution appears to show that while the unfused strategy is more effective at
disrupting the expression of functional GFP (as seen in the fow cytometry data), it
does not necessarily accomplish this by directly interfering with the GFP sequence
itself – it may be causing mutation elsewhere in the genome and indirectly causing
elimination of the fuorescent phenotype. Importantly, the degree of targeting
accomplished by the fusion of the AID to the T7 RNAP appears very high if the results
of the sequencing run are representative of the wider action of the devices.
Most of the mutation events recorded were from the strains which exhibited a loss of
fuorescence; of the 19 events, 14 were from colonies that had lost function and 5 from
those stil expressing functional GFP at the time the target gene was amplifed for
sequencing.  This is in line with the assumption that much of the loss of fuorescence
for the fusion device results from direct disruption of the GFP protein; of the ten fusion
knockout sequences, eight display at least one mutation within GFP and 6 have at least
one mutation resulting in an amino acid change.
Figure 19 shows the distribution of mutations within the GFP gene, and highlights the
prevalence of mutations which are C to T (or G to A), and therefore may likely be
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attributed to AID activity. Mutation events appear evenly spaced throughout the
sequence, with the possible exception of two clusters; one (at the 5 o'clock position in
fgure 19) where 2 mutation events were detected at the same base, with 2 more within
3 amino acids of that site, and another (at the 9 o'clock position) where a C to T
substitution occurred at the same base pair in 4 independent cultures. This may be due
to an uneven transcription rate along the DNA; if transcription progresses slowly or
stals at a point, that area is exposed to assault by AID for longer.
The lack of mutations at the promoter site is a promising result for the tractability of
the system, but the large number of knockouts seen in the unfused samples are
concerning – as fgure 11 showed, the fused and unfused AID constructs exhibit similar
levels of background mutation. Knocking out T7 RNAP functionality would be a boon
to the cel, as it would remove the burden of T7 transcription placed on its metabolism.
If this is happening with unfused AID, it may also be happening with the fusion. It is
possible to ensure T7 RNAP functionality is retained, by expressing a required
antibiotic from a T7 promoter; T7 RNAP knockouts would then not survive. 
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5. Implementation of the system toward an 
orthogonal signal/response pair
5.1.1. Aims
In this chapter, a proof of concept system is devised to apply the T7-AID fusion
towards a real-world application. The chosen target gene is the LasR transcription
factor from Pseudomonas aeruginosa, and the objective is to diversify its specifcity for
its cognate signal molecule. The frst aim, therefore, is to integrate LasR into the E.
coli genome behind PT7. 
Secondly, control circuitry is designed to alow the system to respond to and select for
favourable mutations arising from the action of the fusion protein. This circuitry must
operate in vivo and in real time, to maximise the chance of successful mutation and
minimise the chance of reversion of that favourable mutation by continued attack from
the fusion. The second aim is to construct the genes required for this system on
plasmids, and to co-transform them with the T7-AID device plasmid.
Finaly, the functionality of the control circuitry wil be assessed.
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5.2. System overview
5.2.1. The mutation target: a quorum-sensing system 
As a test case for the system, and as the frst attempt to utilise it toward improving a
specifc target for a specifc need, it was decided that diversifcation of a signal-response
pair would be both approachable and of beneft to the synthetic biology community.
The chosen module was the lasR/PLas system, which responds to levels of the acyl
homoserine lactone (AHL) N-(3-oxododecanoyl)-homoserine lactone, or 3-oxo-C12-HSL,
with increasing transcription from the PLas promoter (Passador 1993; Whiteley 2001).
In the synthetic biology vernacular, the lasR/PLas system is “AHL in, PoPs out”, where
PoPs stands for polymerases per second and represents a measurement unit for
transcription rate at a specifc DNA sequence. A brief overview of the lasR/PLas system
is given here.
One of the most widely-studied, and wel understood, areas of population dynamics in
bacteria is that of quorum sensing (Miler 2001). Quorum sensing is the mechanism by
which bacteria assess the concentration of population in their local space. As the
density of a population of bacteria increases, the bacteria must adapt; slowing growth
and often producing structures or proteins of beneft to their neighbours. These can be
as simple as a low level of antibiotic (Bainton 1992; Duerkop 2009) to attempt to
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cleanse the area of competing species, to complex structures such as bioflms, which
often signal the triggering of virulence factors in pathogenic species (Erickson 2002;
Rutherford 2012). Without this behaviour, growing bacteria might use up al the
resources in an area and cause starvation of the entire population, inhibiting growth or
survival of that species.
Quorum sensing utilises a signal molecule – generaly a chemical such as acyl
homoserine lactone, or AHL, in the case of Gram-negative bacteria or an oligopeptide
in the case of Gram-positive species – which is constantly expressed by al members of
a population to gauge population density (Miler 2001). A high concentration of the
signal molecule implies a high concentration of felow bacteria in an area, and this can
then trigger transcription of genes to take advantage of that via direct action on a
promoter (Gram-negative) or two-component system (Gram-positive) (Bassler 1999).
In the case of the Las system, which is the quorum sensing system in P. aeruginosa,
the key promoter is PLas (Rust 1996; Whiteley 2001). It initiates transcription of lasI
and lasR. lasI encodes a gene which produces 3-oxo-C12-HSL, the quorum-sensing signal
molecule which may diffuse out of the cel into the local environment, and lasR encodes
a protein of the same name which, when bound to that AHL, activates the PLas
promoter. Thus in its native context there is a level of positive feedback; PLas produces
both LasR and the AHL required to alow it to activate PLas (Seed 1995). If activated
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beyond that baseline point, PLas also triggers the transcription of virulence genes
(Winson 1995).
These systems are of great interest to synthetic biologists for many reasons – chief
among them, the hope that biosensor systems designed to detect and respond to these
signal molecules may alow us to modify the behaviour of infectious bacteria. P.
aeruginosa, for instance, is a common bacterium that can cause disease in humans and
can be found in a range of environments including the soil, within buildings, and as
part of human skin fora. It can cause problems in hospitals when it forms bioflms on
indweling medical devices such as catheters, for instance (Parsek 2003).
But there is a secondary reason for the interest in these types of systems, and that is
that they provide an example of a device that could be of great use in designing genetic
circuitry. Signal-response pairs alow communication not only within the cel itself, say
in response to external addition of their inducer, but also between cels; this can be
used to 'synchronise' a population, for instance, or to propagate a reaction (e.g. a
target is detected localy by a subset of a population, which produces the signal
molecule and propagates the signal out to the rest of the population alowing sensitive
detection to produce observable output).
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When building a genetic circuit, methods of communication between different parts of
that circuit quickly become the limiting factor to complexity. This is due to crosstalk;
one cannot utilise the same signal-response pair twice in a cel to different ends, as
when one triggers it wil unavoidably set off both. Thus a variety of devices alowing
connection of two nodes of a circuit without repetition is paramount. Unfortunately, a
limited number of these devices exist which also fulfl other usual requirements –
reliability, non-leakiness, ease-of-use and so on.
The LuxI/LuxR pair from Vibrio fischeri, for instance, is commonly used in synthetic
biology projects (Balagaddé 2005, Basu 2004, McMilen 2002, You 2004) but has a
drawback in that it is relatively promiscuous; it responds to a number of different AHL
molecules to different degrees, inhibiting the use of different quorum sensing systems
together. Figure 20 shows the response curves of part BBa_F2620 (LuxR/PLux) when
presented with various AHL molecules (Canton 2008). It can be seen that it responds
wel to a number of similar AHL molecules – if it could be mutated to lose the ability
to respond to these, and to instead respond to 4AHL for example, an orthogonal signal-
response pair would have been created which could be used in tandem with the original
F2620 device in a circuit.
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Figure 20: Response profile of the PLux system to a range of AHL molecules
Adapted from Canton 2008, this graph shows the response of the PLux inducible promoter
to a range of AHL molecules at increasing concentrations.
Taking LasI/LasR as our test case, the ideal outcome would be to produce a signal-
response pair that specifcaly detects a different AHL than its cognate signal molecule,
3-oxo-C12-HSL. This then opens the door for evolution of multiple orthogonal variants
of the system, each responding to a different inducer; these could be used in paralel
with other AHL-based systems within the same population or the same cel, alowing
complex communication and circuitry to be built on that. It is potentialy even possible
to produce systems that can detect non-AHL type molecules, and thus generate
completely orthogonal bacterial signaling systems or new molecular recognition for use
in biosensor devices.
To attack this problem, the target gene (lasR) would be placed behind the T7 promoter
to expose it to transcription and mutation by the fusion protein. The next step is to
design a mechanism whereby the evolution of a desired variant can be detected and
selected for; a control system is needed.
5.2.2. The control circuit
One of the key benefts of the mutator system described in this report is the ability to
continue mutation over long time periods. Eliminating the need to transfer the DNA
from an in vivo to in vitro environment, and vice-versa, means that continuous
generation of variation is possible; this is within the confnes of the heightened
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background mutation rates and assuming stability of growth, whether using batch
culture, continuous fow, or other methodology.
This advantage can only be utilised effectively however, if there is some method of
eliminating 'overmutation' – that is, mutating past the peak or phenotype which is
aimed for. If culturing a large batch of cels and alowing mutation by the system,
absence of real-time selection methods may cause any successful genetic variants to be
rendered useless or unproductive by continued mutation.
If the phenotype being searched for is an obvious one, as in our test cases with GFP, it
is relatively trivial to design a work-fow; a fuorescence-based cel-sorter could separate
out successful reversions to function of GFP from samples of a culture, for instance, or
be optimised to select out 'interesting' variants of GFP for example. But what of those
products that are not so amenable to selection?
In this section a feedback loop is designed with an eye to fexibility of use. Primarily for
use with the chosen exemplar case to be conducted with the mutator (AHL/LasR pair),
it could be altered to function with any protein that can generate a PoPs output.
The primary design constraint is that upon successful binding of a new AHL to the
mutated LasR protein, mutation should be halted or at least slowed drasticaly. To do
this, a repressor system operating on the promoter producing the AID device is the
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obvious choice. With that said, continued expression of the output molecule is required
for operation of the loop, and thus an alternative polymerase (T7 RNAP alone) should
be produced along with the repressor; this has the added beneft of immediately
competing with the fusion protein for access to the T7 promoter, reducing transcription
by the AID-carrying variant and resultant mutations. Degradation tags added to the
fusion protein could complement and amplify this effect.
The secondary consideration is that of selection. Devising a way to determine which
cels in a culture are 'successful' as far as reaching some target phenotype is important.
With transfers in and out of cels eliminated the limiting step of this methodology, as
far as maintaining the exploration of the greatest sequence space is concerned, is the
screening process. Self-reporting, or self-selection, is a powerful tool in this regard.
To this end, the two most feasible outputs to screen for are fuorescence- and antibiotic
selection-based. Both could alow selection folowed by reintroduction to culture.
Antibiotic selection-based methods seem more attractive, as they alow the elimination
of al failures at a stroke, leaving behind only those candidates who are expressing the
resistance marker, but they also have the downside of potentialy kiling those cels
which are expressing the marker but at too low a level. It was decided that the system
would be designed with both mechanisms, to alow them to be tested and weighed
against each other; the use of both in paralel, elimination of the vast majority of cels
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by antibiotic selection, and the examination of the rest using fuorescence-based tools,
would be optimal in the end case.
The completed system design is shown in fgure 22.
As the feedback loop initiates, the mutator and unfused T7 wil compete for the T7
promoter. If the target is not producing a strong enough output (say, only very weakly
binding the AHL molecule) then it is conceivable that the mutator may not be fuly
repressed until further mutations strengthen the target or eliminate its activity. This
alows the mutator system to scale mutation as a target functionality is approached, a
powerful additional beneft, though it does carry with it an attenuated risk of over-
mutation. Such an effect may be tuned by the strength and reliability of the repressor
system.
5.2.3. Leakiness
Inducible promoters are one of the most widely-available, and widely-used, parts in the
synthetic biologist's tool kit. They add functionality to a circuit to alow output to be
controled by some input, often an inducer molecule. This control function may be
binary (on/off in the presence or absence of inducer) or may folow a dose-response
curve, alowing fner control and responsiveness for a circuit – as exemplifed earlier in
fgure 20, the response curves of LasR/PLas when presented with varying AHLs.
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One common feature of inducible promoters which is generaly seen as a drawback is
leakiness. This is the baseline expression from the promoter in the absence of inducer;
in a simple biosensor, for example, leakiness could cause continued low-level expression
of the signal molecule which may build up and trigger a false-positive result. The
mechanisms by which a promoter may be leaky vary, depending on the type of
interaction that is blocking transcription normaly – some promoters rely on physical
structures within their DNA and associated operator regions to interfere or obscure the
binding site until disrupted by some inducer; others may require some cofactor which
can only bind in the presence of their inducer and so on. Thus leakiness may be
realised by simple stochastic disruption of an inhibitor, by interference/competitive
binding from a homologous molecule, or by low-level background levels of inducer and
so on.
Several approaches designed to eliminate leakiness from, or produce tight alternatives
to, available inducible promoters have been tried. Beyond specifc engineering of
promoter control sequences in an attempt to eliminate stochastic disruption (Alper
2005), or construction of novel promoters, some attempts have been made to alter the
downstream bases into the RBS and gene (Guzman 1995). One promising and diverse
avenue of research is RNA control; for instance, using a stretch of interfering/silencing
RNA to inhibit ribosome binding by attaching to mRNA at that point and denying
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translation (Morita 2006). These efforts progress to the more ambitious and innovative
schemas such as the use of recombinases to invert a target, fuly denying transcription
until the gene is reoriented the correct way around (Ham 2006; Friedland 2009).
Cel-cel variability is the name given to the phenomenon whereby a range of
phenotypes may arise in a given population of identical cels in an identical
environment (Elowitz 2002, Pelkmans 2012). Stochastic effects combine with the cels'
genetic 'programming' to alow diversifcation. This is evolutionarily favourable,
alowing exploitation of various niches or substrates within that environment, or
survival of some sub-population folowing a catastrophic event affecting the main
population, but it is also a source of frustration in the laboratory; al cels are not
equal, and population effects and single-cel effects may not be linked with ease.
Extrinsic noise, that arising from the environment, may be controled for in the
laboratory; intrinsic noise, however, the variability of expression inherent in any process
reliant on biochemical reactions at the molecular scale, cannot. One major component
of that noise, an amplifying factor, is the phenomenon of burst transcription. When an
mRNA is produced it causes some variable number of translation events and each of
these 'bursts' of resultant protein production are distributed randomly and
independently, folowing a Poisson distribution (Spudich 1976, McAdams 1997).
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Linking this idea back to leakiness, it can be seen that even relatively rare transcription
events such as those arising from a leaky promoter may cause non-trivial production of
protein and interfere with downstream circuitry.
In the case of the mutator system, this is of great relevance when designing the
feedback circuitry which is supposed to shut down the mutator upon successful
production of a target.
Control of leakiness in such a circuit is of paramount importance if that beneft is to be
realised; continued expression of AID could cause loss of useful function generated by
that molecule. Additionaly, leakiness of the 'shut down' circuit when it is not required
would cause a decrease in efciency of the mutator system in culture.
Looking at the test case that was chosen – the AHL/LasR response pair – it could be
seen that these promoters have a degree of leakiness and non-specifcity (Chappel,
2013). It would be valuable, therefore, to be able to implement a control loop even
under the constraints of the leaky promoters.
5.2.4. Bacterial logic gates, circuit design 
To do this, an engineering solution to the problem was devised. Using a logic gate, a
ubiquitous feature in computing and relatively commonly approached as a project by
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synthetic biologists, it was hoped that the unique properties of a genetic circuit may
alow construction of a novel gate device which could act as a 'high-pass' flter, fltering
out low-level activation of a promoter while retaining the action at higher
concentrations of inducer (including the dose-response profle).
At the simplest level, the proposed device is an AND gate with two identical inputs. A
non-sensical device in electronics, several properties of genetic circuits give reason to
believe that such an arrangement could have interesting properties in the genetic
context: the stochastic nature of gene activation and transcription, discussed earlier,
and the delay between that activation and expression of the output molecule key
among them.
With a leaky promoter in front of an output gene, any stochastic fring from that
promoter wil result in some number of mRNAs. Each of those mRNAs may then result
in some variable number of proteins being produced. Placing the gene behind two
identical promoters in series may cause increased expression, both reading into the
gene; placing them in paralel on the DNA, such that both must be activated to alow
transcription, is not an available option. If we use a genetic logic gate, however, and
decouple the input and output via a mediator, we can achieve the functional equivalent.
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If two identical promoters trigger the production of two non-identical products, and if
both those products are required to activate a promoter in front of that actual desired
output, then only when both are triggered (within some time period dependent on the
lifetime of the intermediate proteins) wil any output be produced. Effectively, given
that stochastic transcription is somewhat rare, the likelihood of producing output
without induction decreases multiplicatively; whereas before any activation of a
promoter would cause output, now only when both fre together wil output be seen.
When we look at the case where the promoters are actively induced, however, there
should be some stable level of both AND gate proteins in the cel at al times and
output wil be constant depending on that level. Thus the dose response curve and
activity of the system at upper ranges can be conserved, while eliminating low-level
expression occurring as a result of stochastic fring or noise. The described device
should operate as a high-pass flter, but requires the folowing conditions be met:
1.Zero leakiness of the output promoter, the one triggered by the combined AND
gate products; 
2.AND gate products with a shorter lifetime than the median time between
stochastic bursts; 
3.Input promoters with a consistent activity when activated.
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A review of the literature shows a number of AND gate systems have been built in a
biological context (Anderson 2007; Ramalingam 2009; Sayut 2009). Of particular
interest was one created by Wang et al. (2011). Along with meeting al the
requirements outlined above, it had the added benefts of extensive characterisation,
and convenience; the work was done at Imperial Colege, and al constructs and
component parts were readily available.
Wang's AND gate (fgure 21) comprises a sigma-54 promoter (PHrp) and the genes
required to produce two proteins (HrpR and HrpS). Triggering transcription of those
genes simultaneously alows PHrp to transcribe its target. Sigma-54 promoters are linked
to the stress response in E. coli, and sigma-54, RNA polymerase and DNA very rarely
form open complex spontaneously as compared to sigma-70 promoters (Buck 2006),
meaning that the system displays minimal leakiness. Importantly, the Hrp system is
native to Pseudomonas syringae, and does not interact with E. coli systems: when
transported into the preferred host, its action is insulated from the chassis' background.
The characterisation of this system included transfer functions using two inducible
inputs and a fuorescent output, and demonstrated extremely tight control of leakiness
and specifcity of operation (Wang 2011). The orthogonality provided by its use in an
E. coli chassis was also attractive, as it matched the intended host strain. By replacing
the input promoters – that is, those that serve to transcribe HrpR and HrpS – with the
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PLas promoter, it should be possible to exert tight control over the system and alow
trial of the AND-gate-as-flter theory.
With these considerations in mind, the circuit was designed as folows (see fgure 22).
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Figure 22: Schematic of AND gate and control circuitry
Parts in grey represent the mutator/target system. Those in blue are the AND gate and
lasR/PLas circuit, with red being the feedback loop to prevent overmutation and green
the reporter genes to enable screening/selection.
Figure 21: The HrpR/S-based AND gate
Adapted from Wang 2011, this genetic circuit diagram shows that any two inducible
promoters (P1 & P2) may be linked to the production of HrpR and HrpS; upon
simultaneous transcription of both, Phrp may be activated to produce an output.
5.3. Results
5.3.1. Construction
Construction of the target and control circuitry was performed in paralel. This alowed
testing to begin on each part individualy, in the order they were completed, before
combinatorial testing began.
The PLas testing construct was designed and constructed both with and without the
AND gate described in the introduction to this chapter, and was inserted onto a high-
copy backbone. The LasR target was inserted into pAH153 for integration. The
mutator protein was transferred to and co-transformed on a low-copy backbone (pC5).
The disparity in copy number between the mutator and the control circuitry should
serve to alow tighter control of the mutator in the fnal system – in a mirror of the
original construction logic outlined in section 2.4.2 which placed the mutator on the
high copy backbone with the target on a low one, to ensure saturation of transcription.
Since the testing constructs do not include the ful circuitry, the high copy merely
provides a more obvious output from successful expression.
Al assembly was carried out using Gibson (7.2.6) or CPEC (7.2.7) cloning. Each of the
four resulting plasmids was purifed and sequence-verifed (7.3.1) and are shown in
fgure 23.
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Figure 23: The PLas diversification and reporting devices, with and without AND gate
Top, left: pA3:PLas-GFP, containing GFP under PLas control with the weak RBS33. Top,
right: pA3:PLas-AND-GFP, containing the components of the AND gate (hrpR/S) under
PLas control and GFP under PHrp. Al modules use the weak RBS33.
Botom, left: pCRIM:LasR, containing LasR under PT7 on the pAH153 plasmid for
integration into the genome. Botom, right: pC5:TA, the fusion protein on a low-copy
backbone.
As the target, LasR was integrated into the GM31 genome folowing the standard
CRIM procedure (7.2.12) and the integrated cassette was amplifed and sequenced to
ensure sequence veracity. GFP was also integrated into GM31, for use as a positive
control in later stages. Upon confrmation of successful and correct integration, these
strains was termed GM31-LasR and GM31-GFP.
5.3.2. Testing
Having been made electrocompetent (7.4.3), GM31-LasR and GM31-GFP were
transformed as folows:
GM31-LasR
1.pUC19 (negative control)
2.pA3:PLas-GFP & pC5:T
3.pA3:PHrp-AND-GFP & pC5:T
GM31-GFP
1.pC5:T (positive control)
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These permutations alowed comparison of both LasR-controled GFP expression –
both as a raw input and mediated by the Hrp-based AND gate – to benchmark
constitutive or zero expression of the GFP molecule.
This was performed on a fuorescence microplate reader with later tests, such as
examining leakiness of straight-through and AND-mediated systems which demanded
greater granularity, to be performed on a fow cytometer.
The frst round of experiments, cultures over 24 hours with 12-hour sampling times
post-induction, yielded unexpected results (fgures 24 & 26). They showed no
discernable difference in output (as determined by the measured fuorescence, corrected
for background and normalised for cel density by division of the corrected fuorescence
value by the corrected OD600 value) between those cultures induced or uninduced by
AHL. Indeed, no output at al was detected, with the exception of the positive control
(GM31-GFP(pC5:T)).
To rule out growth differences between constructs, the growth curves from the above
experiments were examined in greater detail. These revealed no signifcant differences
between the different constructs (see fgure 25). It was therefore considered that the
most likely source of the problem was the AHL-induced LasR induction. 
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Figure 24: Induction of the LasR/PLas system by AHL failed
Time runs from 0-12 h post-induction with 1 µM AHL for al figures on this page.
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Figure 25: Growth curve for LasR testing constructs
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Figure 26: Fluorescence detection is validated with a positive control
Standard error of triplicate repeats is shown, demonstrating consistency between
repeats.
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Since LasR is chromosomaly integrated there are fewer copies than on previously
studied plasmid based systems (Chappel 2013). For comparison we therefore included
a control plasmid that expresses LasR from the constitutive BBa_J23101 promoter
(pA3-lasR-pLas-GFP). This combination produced the expected result, shown in fgure
27, demonstrating that the induction procedure was not at fault.
To assess whether the level of T7 RNAP in the cel was too low to generate enough fux
through the circuit, GM31-GFP(pC5:T) was tested with a range of IPTG
concentrations. The results (fgure 28) demonstrate that the level of T7 RNAP
produced merely by leakiness from the lac promoter preceding it is enough to cause ful
transcription of GFP behind the single PT7 in the cel – at al concentrations of inducer,
including uninduced, there is an equal level of fuorescence output.
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Figure 27: The original LasR system responds to induction with 1 µM AHL
Here, LasR is a positive control plasmid that constitutively expresses LasR and has
GFP under a PLas promoter. pA3:PLas-GFP and pA3:PLas-AND-GFP response to
AHL induction are also shown, alongside HrpL. Time runs from 0-3 h post-induction.
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Figure 28: PLac-T7RNAP induced with IPTG shows strong expression
Time runs from 0-2 h post-induction.
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To assess whether the level of LasR in the cel could be the cause, GM31-
LasR(pA3:PLas-GFP) & pC5:T) and GM31-LasR(pA3:lasR-pLas-GFP) were both
cultured, induced, then lysed and examined using SDS-PAGE. This gel is annotated
and presented as fgure 29. The control experiment shows a large band at 26.91 kDa
(corresponding to GFP) in the induced sample, but no band in the uninduced sample.
In the case of GM31-LasR(pA3:PLas-GFP & pC5:T), a band is seen at 26.6 kDa in both
uninduced and induced samples – this corresponds to overproduction of LasR by the
cel, but no successful 'conversion' to GFP output upon induction. This ruled out LasR
production levels being a limiting factor, and strongly indicated that the problem lay in
the output circuitry.
Having thus eliminated a number of the most obvious issues which could cause failure
of the system in the manner described, only a narrow feld of choices remain – the most
likely candidate for further scrutiny was the weak RBS (RBS33) preceding the outputs
and control genes on pA3:PLas-GFP/PHrp-GFP. These were marked for removal and
replacement via CPEC, with primers being designed accordingly.
Upon successful replacement of the RBS with RBS34, the plasmids were re-transformed
and GM31-LasR(pA3:PLas-34-GFP & pC5:T7) was tested using fow cytometry. As seen
in fgure 30, these data showed the expected pattern, with the induced and uninduced
sample peaks faling between the negative and positive controls. The leakiness
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suggested by the presence of a peak in the uninduced samples is therefore the next
point of interest to be examined; it is this leakiness that it is hoped wil be ameliorated
by the use of the AND gate.
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Figure 29: SDS-PAGE gel confirming expression of LasR
LasR shows a band at 26.6 kDa. GFP shows at 26.91 kDa – it is present
in the control sample.
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Figure 30: Flow cytometry data showing function of the LasR circuit, and response to
induction
Top: negative control (black), GFP behind PLas uninduced (red) and induced (blue) and
GFP behind T7 RNAP positive (green) histograms are shown. The plot is divided into
regions FL- and FL+. 
Botom: Cel count data showing the distribution of cels between FL- and FL+.
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6. Conclusion
The primary aim of the project, to produce a system for the targeted directed evolution
of proteins, has been achieved. Experiments involving the mutation of a single-copy
target, integrated onto the genome of an E. coli chassis, have shown that the fusion of
T7 RNA polymerase and AID brings to bear a signifcant targeted mutation effect in
line with the objective of the device. Examination of the mutational landscape
demonstrates an even spread of mutation along the target sequence which is far above
background rate.
Signifcant progress has also been made toward the secondary aims, namely assessment
of both the exact level of mutation and the degree to which mutation is targeted – loss
of function assays have determined that masking may be ignored in any future gain-of
function assay designed to calculate an accurate mutation rate for the device. The
targets for such an assay have been produced. Integration of those targets and
repetition of the single-copy analysis protocol, designed and optimised in this work, wil
alow such an accurate determination to be made.
The groundwork has been laid for diversifcation of LasR as a proof of concept, with
technical issues of circuit design and development successfuly solved. Data produced
after the completion of the project, but using constructs and methods created and
119
optimised in this work demonstrated that the novel adaptation of an AND gate as a
bandpass flter successfuly reduces leaky expression in the designed control circuitry
(fgure 31). This wil alow transformation of a self-contained mutation and screening
device as designed here.
The focus of the project moving forward rests on augmentation of the system.
Expressing a uracil DNA glycosylase inhibitor protein inducibly with the fusion in a
non repair-defcient strain, and repressing it when the fusion is disabled by the control
circuitry, could serve to reduce post-success mutation events while stil offering the
advantage of preserving mutations introduced by AID in the diversifcation stages.
Addition of a second AID molecule to the fusion, presenting greater opportunity for
dimerisation to occur, could serve to increase the mutation rate of the system and is an
avenue that demands exploration.
Tertiary aims, including the retention of compatibility of construction with Synthetic
Biology techniques and the improvement of efciency of work-fow in the Synthetic
Biology labs at Imperial Colege were also achieved – the procurement of a liquid
handler, and adaptation of the automation protocols developed during this project have
led to streamlining of a number of tasks at the Centre for Synthetic Biology and
Innovation, with high-throughput experimentation now routine.
120
121
Figure 31: Flow cytometry showing the LasR circuit and AND gate circuit responding
to AHL induction
Adapted from Storch 2013 (unpublished data). Response of the AND gate post-RBS
replacement demonstrates functionality. Note GFP has an LVA degradation tag added,
in an atempt to reduce build-up of leaky expression.
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7. Methods
7.1. Tables
7.1.1. Strains
Strain Genotype Purpose Reference
E. coli 
GM31
F- Thr-1, araC14, leuB6(Am), fhuA31, lacY1, tsx-
78, glnV44(AS), galK2(Oc), galT22, λ-, dcm-6, 
hisG4(Oc), rpsL136(strR), xylA5, mtl-1, thiE1
Plasmid 
storage and 
isolation
Marinus 1973
E. coli 
BH156
GM31 ung-1 tyrA∷Tn10 BER pathway 
knockout
Lutsenko 
1999
E. coli 
BH156-GFP
GM31 ung-1 tyrA∷Tn10atф80∷[gfp]
Single-copy 
target analysis 
(loss of 
function)
This work
E. coli 
BH156-XFP
GM31 ung-1 tyrA:Tn10 atф80∷[xfp]
Single-copy 
target analysis 
(reversion to 
function)
This work
E. coli 
GM31-LasR
GM31 atф80∷[lasR]
Proof of 
concept 
diversifcation
This work
E. coli 
GM31-GFP
GM31 atф80∷[gfp]
Proof of 
concept 
diversifcation
This work
E. coli 
BL21(DE3)
F- ompT hsdSB (rB-mB-) gal dcm lon λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5])
Native T7 
RNA 
polymerase
NEB catalog 
#C2527
E. coli 
TransforMa
x EC100D 
pir+ 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZΔM15 
ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 
galU galK λ- rpsL (StrR) nupG pir+(DHFR)
Alows 
propagation of 
CRIM plasmids
Epicentre 
Biotech-
nologies
Table 3: Key strains used in this work
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7.1.2. Plasmids
Name Construct Description Reference
pCD pACYC-Duet  backbone;
chloramphenicol resistance, p15A ori,
10-12 copies per cel.
Registry  of
Standard
Biological Parts
pC5 pSB4C5 backbone; chloramphenicol
resistance, pSC101 ori, ~5 copies per
cel.
Registry  of
Standard
Biological Parts
pA3 pSB1AK3 backbone; Amp/Kan
resistance, pMB1 ori, 100-300 copies
per cel.
Novagen
pA3:TA PLac-RBS32-AID-
T7RNAP-XX
AID-T7RNAP fusion This work
pA3:T PLac-RBS32-T7RNAP-XX T7RNAP This work
pA3:T+A PLac-RBS32-AID-XX-PLac-
RBS32-T7RNAP-XX
T7RNAP, AID This work
pAH153  &
pAH123
CRIM integration & helper plasmid
pair
Haldimann
2001
pCD:PT7-GFP PT7-RBS34-GFP-XX GFP under PT7 This work
pC5:PT7-GFP PT7-RBS34-GFP-XX GFP under PT7 This work
pCD:PT7-XFP PT7-RBS34-XFP-XX XFP under PT7 This work
pC5:PT7-XFP PT7-RBS34-XFP-XX XFP under PT7 This work
pCRIM:GFP PT7-RBS34-GFP-XX GFP under PT7 This work
pA3:PLas-GFP PLas-RBS33-GFP-XX GFP under PLas This work
pA3:PLas-
AND-GFP
PLas-RBS33-HrpR-XX-
PLas-RBS33-hrpS-XX-
PHrp-RBS33-GFP-XX
GFP under AND gate control, with
AND gate proteins under control of
PLas. 
This work
pCRIM:LasR PT7-RBS34-LasR-XX LasR under PT7 This work
pC5:T PLac-RBS32-T7RNAP-XX T7 RNAP under PLac This work
Table 4: Key plasmids used in this work
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7.1.3. Primers
Name Sequence Purpose
VF2 TGCCACCTGACGTCTAAGAA Sequencing constructs in 
BioBrick vectorsVR ATTACCGCCTTTGAGTGAGC
T7F atgAACACGATTAACATCGCTAAGAAC Extracting T7 in pSB1AK3 and 
adding a start codonT7R gttaatcgtgttCATCTAGTACTTTCCTGTGTGAC
AIDF TAATAATACTAGAGCCAGGCATC Extracting AID in pSB1AK3 
and adding a stop codonAIDR gctctagtattattaCTGACCGGTTAAACCCAG
KanS_GF gaggagaaatactagATGATTGAACAAGATGGATT
G Extract and add overhangs to 
kanS for InFusion
KanS_GR gatgcctggctctagtaTCAGAAGAACTCGTCAAG
KanS_VF TACTAGAGCCAGGCATC Remove GFP target from vector, 
linearise for kanS InFusionKanS_VR CTAGTATTTCTCCTCTTTAATCTC
GFPtoXFP_
SDM_F
CTTGTCACTACTTTCGGTCATGGTGTTCAA
TGCTTTGC Site-directed mutagenesis (GFP-
XFP)GFPtoXFP_
SDM_R
GCAAAGCATTGAACACCATGACCGAAAGTA
GTGACAAG 
CRIM_Gene
_F gagccctactccatacgGTTGATCGGGCACGT Extract GFP/XFP/kan
S targets
for CPEC into pAH153
CRIM_Gene
_R ccgccttgaacgaattGGTCTGACAGCTCTAGC
CRIM_153_
F gctagagctgtcagaccAATTCGTTCAAGGCGG Linearise pAH153 for CPEC of
GFP/XFP/kanS targets
CRIM_153_
R acgtgcccgatcaacCGTATGGAGTAGGGCTC
Phi80_P1 CTGCTTGTGGTGGTGAAT Phi80-specifc integration check
CRIM_P2 ACTTAACGGCTGACATGG
CRIM integration check
CRIM_P3 ACGAGTATCGAGATGGCA
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CRIM_T3 ACGGTGGTATATCCCGTG
Modifed CRIM_P3 for use with 
pAH153 variants made in this 
work
Phi80_P4 TAAGGCAAGACGATCAGG Phi80-specifc integration check
SB_vector_
CPECF
agcggtatcaGCTCACTCAAAGGCGGTAAT
Linearisation of SB vectors for 
CPEC/GibsonSB_vector_
CPECR
catgataataatggtTTCTTAGACGTCAGGTGGCA
LasR_F gcttctagagtaatacgactcactataTACTAGAGAAAGA
GGAGAAATACTAGATGG Extract RBS34-LasR for putting 
in pCRIM
LasR_R tcatccatgccatgtgtaatcccaGCCTGGCTCTAGTAT
TATTAGAGAG
pCRIM_F cctctctaataatactagagccaggcTGGGATTACACATG
GCATGGATGA Linearise pCRIM for 
CPEC/Gibson
pCRIM_R catctagtatttctcctctttctctagtaTATAGTGAGTCGT
ATTACTCTAGAAGC
Rsh_GFP_i
n_153
TTGCATGCCTGCAGC Sequencing of target in 
pAH153/amplifcation of 
genomic targetsFsh_GFP_i
n_153
GCCTCGCTTTGTAACGG
Flo_GFP_in
_153
GCCTCGCTTTGTAACGG
As above but further from the 
targetRlo_GFP_i
n_153
ACAGGCTTATGTCAACTGG
Table 5: Key primers used in this work
Sequences in lower case are overhangs which do not initialy bind to the target DNA
sequence; sequence in capitals corresponds to the DNA-binding sequence.
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7.2. DNA construction and manipulation
7.2.1. Plasmid isolation
For DNA construction purposes, plasmid DNA was purifed from 3 ml overnight cel
cultures using the E.Z.N.A. plasmid mini kit (Omega Bio-tek) or QIAprep mini kit
(QIAGEN), folowing the manufacturer’s protocol. Automated methods are described
in 7.5.2.
The QIAprep protocol was adapted to avoid the use of spin columns when sample
number was high. The modifed protocol was as folows:
Cels were peleted in a microcentrifuge tube in a bench-top centrifuge, and
resuspended in 150 µl buffer P1. 150 µl buffer P2 was added, and the tube mixed by
inversion. This was repeated with 210 µl buffer N3, and the resulting mixture was spun
down in a benchtop microcentrifuge for 10 minutes. 450 µl supernatant was mixed with
900 µl ethanol by inversion, before a second 10 minute centrifuge step. Supernatant was
discarded and the pelet washed by vortexing in 0.5 ml 70% ethanol. A fnal spin step
of 1 minute was carried out, and the supernatant discarded. The pelet was dried and
resuspended in 30-50 µl ddH20.
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7.2.2. PCR
Standard PCR was carried out in reactions containing 1 U Pfu Turbo Cx (Agilent
Genomics), 0.2 mM of each dNTP, 1× PC2 buffer, 0.4 µM each primer, 50 ng template
DNA, and ddH2O up to a fnal volume of 25 µl.
PC2 buffer (Barnes 1994) was composed of 20 mM Tris-HCl (pH 8.5), 150 mg/ml
bovine serum albumin, 16 mM (NH4)2SO4, and 3.5 mM MgCl2.
The PCR program used had the folowing steps: (i) initial denaturation for 2 min at
95°C; (i) 30 cycles consisting of  30 s denaturing at  95°C, 30 s  annealing at 55-65°C,
1 min/kb extension at  72°C; (ii) fnal extension for 2 min at 72°C. An Applied
Biosystems 2720 thermal cycler was used.
For downstream applications requiring high-fdelity amplifcation, such as Gibson or
CPEC DNA assembly, Phusion High-Fidelity enzyme (NEB) was used instead of Pfu
Turbo Cx. The protocol described above was folowed with two modifcations: 1×
Phusion HF Buffer was used instead of PC2 Buffer, and extension time was calculated
as 15 s/kb plus an additional 15 s.
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7.2.3. Colony PCR
Colony PCR was carried out using the same protocol as described in section 7.2.2, with
the folowing modifcations: (i) single colonies were picked and re-suspended in 20 µl
ddH2O, then 1 µl was used as DNA template; (i) the initial denaturation step was
increased to 5 min at 95°C.
7.2.4. Site-directed mutagenesis
Site-directed mutagenesis was conducted folowing the manufacturer’s instructions in
the Stratagene QuikChange Site-directed Mutagenesis kit (now supplied by Agilent).
The thermal cycling program used was programmed as folows: initial 30 s at 95°C,
then 16 cycles of 30 s at 95°C, 1 min at 48-57°C, and 1 min/kb at 72°C. The PCR
product was incubated with 10 U DpnI (NEB) for 1 h at 37°C to digest template DNA.
It was then transformed into E. coli. 
7.2.5. In-Fusion assembly
The In-Fusion HD Cloning Plus kit (Clontech) was used for scarless assembly of DNA
fragments , according to the manufacturer's instructions. 
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7.2.6. Gibson isothermal assembly
Gibson isothermal assembly protocol was applied as described by Gibson et al (2009)
folowing their 'one-step isothermal DNA assembly protocol'. Briefy, DNA fragments
were amplifed by PCR with primers with 5’ overhangs to generate approximately 40
bp overlap sequences. 100 ng of the largest DNA molecule and equimolar mass of
smaler molecules were incubated with the reagent-enzyme mix, prepared as described
(Gibson 2009), at 50°C for 1 h. 1 µl of the assembly reaction was used to transform
electro-competent E. coli cels. 
7.2.7. CPEC
Circular Polymerase Extension Cloning (CPEC) was performed as described by Quan
and Tian (2009). The DNA molecules with overlapping end sequences were generated
using the same method as in Gibson assembly (section 7.2.6). Electro-competent E. coli
cels were transformed with 0.5 µl of the CPEC. 
7.2.8. BioBrick cloning
The BioBrick assembly standard is a standardised restriction digest cloning strategy
suitable for assembling parts from the Parts Registry (parts.igem.org). The protocol
requires double-enzyme digestion of DNA parts and vector, folowed by
dephosphorylation of digested vector, and ligation of parts with vector (Shetty 2008). 
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7.2.9. Digestion
Al restriction enzymes used were supplied by NEB. Generaly, 10 U enzyme was used
per 500 ng DNA, and incubated for 1 h at 37°C in the appropriate 1× buffer (chosen
based on manufacturer’s instructions). 
7.2.10. Dephosphorylation
Linearised vectors were treated with Antarctic Phosphatase (NEB) to reduce self-
ligation, folowing the manufacturer’s protocol. 
7.2.11. Ligation
DNA insert and vector were ligated using T4 DNA ligase (NEB). A 3:1 equimolar ratio
of insert to vector was used, with 50 ng vector. DNA was added to a 20 µl reaction
mix, with 400 U T4 DNA ligase and 1× T4 DNA ligase buffer, and incubated for 2 h at
room temperature. Ligase was inactivated by incubation at 65°C for 10 minutes.
7.2.12. CRIM integration
Targets were integrated in to the E. coli genome using the Conditional-Replication,
Integration, and Modular (CRIM) plasmid system. The protocol was folowed as
described in Haldimann et al (2001), with the pir+ cel strain used for plasmid
propagation described in section 7.1.1.
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Confrmation of successful integration was carried out with the 4-way PCR described in
Haldimann 2001, but with a slightly modifed 'P3' primer (CRIM_T3 in table 5).
7.3. Quantifcation
7.3.1. DNA concentration & sequence verification
The concentration of DNA was measured using the NanoDrop 1000 spectrophotometer
(Thermo Scientifc) to determine absorbance at 260 nm. Sequence verifcation of
purifed DNA was performed by MWG Eurofns Operon.
7.3.2. Gel electrophoresis/extraction
Agarose gels were prepared with 1% w/v agarose and 1× Tris-Borate-EDTA (TBE)
buffer. DNA samples were loaded with 1× SYBR Green (Life technologies). Gels were
run at 120 V, and 1 kB DNA ladder (NEB) was used as a size reference. Bands were
visualised using one of two imagers; a LAS-3000 or a FLA-5000 (both Fuji). LAS-3000
employed 460 nm LED light source and Y515Di flter. FLA-5000 employed 47s nm laser
light source with Y510 flter.
For isolation of DNA from agarose gels, the QIAQuick Gel Extraction kit (Qiagen) was
used according to manufacturer’s protocol. 
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7.3.3. SDS-PAGE
Cels were cultured in LB media to an OD at 600 nm of 0.6. They were then induced as
appropriate and cultured overnight. 500 µl of culture was spun down in a bench top
centrifuge and resuspended to a volume of 200 µl. This sample was heated to 95C for
0.5 h, then spun down. The supernatant was added to 50 µl of loading buffer (at 5x
stock). 30 µl samples were loaded onto the gel.
The gel itself consisted of a 12% resolving gel (5 ml consisting of 1.6 ml ddH2O; 2 ml
30/0.8% acrylamide/bis; 1.27 ml 1.5 M Tris at pH 8.8; 50 µl 10% SDS; 67 µl 10%
ammonium persulfate and 7.1 ml TEMED) and a 5% stacking gel (5 ml consisting of
3.4 ml ddH2O; 0.83 ml 30%/0.8 acrylamide/bis; 0.63 ml 1 M Tris at pH 6.8; 50 µl 10%
SDS; 50 µl 10% ammonium persulfate and 10 µl TEMED), and was run for 15 minutes
at 80 V and 80 minutes at 160 V. Staining and destaining used a solution of 40%
methanol, 7% acetic acid, with 0.025% Coomassie Briliant Blue added for the staining
step which consisted of 2 minutes heating at low power in the microwave folowed by 20
minutes shaking incubation in the dark.
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7.4. Cultures & propagation
7.4.1. Cultures
Media used was either LB (tryptone at 10 g/l; yeast extract at 5 g/l; NaCl at 5 g/l in
ddH2O) or autoinducing media from Formedium (made up according to manufacturer's
directions, 37.5 g/l).  For agar plates, 7.5 g/l agar was added. Antibiotics were used as
appropriate, with fnal concentrations being as folows: Amp – 100 µg/ml; Cam – 34
µg/ml; Kan – 25 µg/ml; Gent – 20 µg/ml; Rif – 50 µg/ml.
For general purposes, cels were diluted 1:1000 into, or picked from colonies using a
sterile pipette tip which was ejected into, a glass test tube containing 3 ml of either LB
or auto-inducing media as required. This media was supplemented with appropriate
antibiotic from 1,000× stock, and the tube capped and incubated at 37°C with shaking
at 222 rpm unless otherwise stated.
For the each culture of the multi-copy and single-copy assessment runs, 1 ml pre-
warmed auto-inducing media supplemented with the appropriate antibiotic was
inoculated from an individual colony picked from a transformation plate. These were
incubated at 37°C for 2 hours, with shaking at 222 rpm. At this time, 10 µl of culture
was diluted 1:100 and 1:10,000 in fresh media, 100 µl of which was plated on AI plates
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with the appropriate antibiotic. The remainder of the culture was spun down in a
bench-top centrifuge and stored at 4°C overnight, while the plates were stored at 37°C.
The dilution plates were scored the folowing morning to assess the number of colony-
forming units (CFU) per ml of culture. This value was used to determine the volume of
stored culture required to inoculate a 13 ml 'starter culture', consisting of LB with
appropriate antibiotic with 20% glycerol, to ensure that the initial CFU of cultures in
the runs was low enough (100-150) to conform to the assumptions listed in table 1.
Starter cultures were kept at -20°C, and used as seed stocks to inoculate each run.
7.4.2. Chemicaly-competent cels/chemical transformation
Chemicaly-competent cels were prepared based on a modifed protocol from Sambrook
and Russel, third edition (2001). A starter culture was prepared by inoculating a single
colony into 5 ml of LB medium and incubating for 16 h at 37°C with shaking at 222
rpm. 100 ml LB medium was inoculated with 1 ml of the starter culture, and then
grown at 37°C until OD600 reached 0.6-0.8. The culture was pre-chiled for 15 min on ice
before centrifugation for 5 min at 4,000 RCF and 4°C.  The supernatant was removed
and the pelet re-suspended in 10 ml ice-cold 0.1 M CaCl2 and incubated on ice for 20
min. The centrifuge step was then repeated, the supernatant discarded and cels were
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resuspended in 5 ml ice-cold 0.1 M CaCl2 with 15% glycerol. The cels were stored in
aliquots of 210 µl at -80°C. 
For transformation, 0.5-1 µl plasmid DNA and 100 µl cels were placed in a pre-chiled
microcentrifuge tube on ice, and incubated for 30 minutes. The microcentrifuge tube
was transferred to a waterbath or heatblock at 42°C for 2 minutes, then returned to the
ice. 900 µl pre-warmed LB medium was added to the tube, which was incubated for 30
minutes at 37°C with 222 rpm shaking. Dilutions of the cels were plated on the
appropriate antibiotic-supplemented media and incubated overnight at 37°C.
A variant of the transformation protocol for use on an automated platform is described
in 7.5.3.
7.4.3. Electro-competent cels/electroporation
Electrocompetent cels were prepared based on a modifed protocol from Sambrook and
Russel, third edition (2001). A starter culture was prepared by inoculating a single
colony into 50 ml of LB medium and incubating for 16 h at 37°C with 222 rpm. 1 l LB
medium was inoculated to an OD600 of 0.1 using the starter culture, and then grown at
37°C until OD600 reached 0.6-0.8. The culture was pre-chiled for 15 min on ice before
centrifugation for 15 min at 4,000 RCF and 4°C.  The supernatant was removed and
the pelet re-suspended in 1 L ice-cold ddH2O. The centrifuge step was repeated three
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times, with subsequent washes in 0.5 L ddH2O, 20 ml sterile 10% glycerol, then 2.5 ml
10% glycerol. The cels were stored in aliquots of 125 µl at -80°C. 
For transformation, 0.5-1 µl DNA and 40 µl cels were placed in a pre-chiled 1 mm
electroporation cuvette. The sample was electroporated using a BioRad GenePulser
with the conditions 1.8 kV, 200 Ω, and 25 µF. 1 ml pre-warmed LB medium was added
to the cuvette, then the mixture was transferred to a microcentrifuge tube and
incubated for 1 h at 37°C with 222 rpm shaking. Dilutions of the cels were plated on
the appropriate antibiotic-supplemented media and incubated overnight at 37°C.
7.4.4. Glycerol stocks
For long-term storage of bacterial strains, overnight cultures were prepared by
inoculation of a single colony in 3 ml LB media supplemented with the appropriate
antibiotic. Glycerol was added after 18 h growth to a fnal concentration of 20% in 1 ml
total volume, and the stocks were stored at -80°C.
7.5. Automation
The protocols for the automated versions of several lab procedures which were
developed are described in general terms below; the programs themselves may be found
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in appendix 9.2. Al automation was performed on a TheONYX liquid handler (Aviso
GMBH).
7.5.1. Preparation
Culturing was performed as described in section 7.4.1 with inoculation at 150 CFU. 2
ml of each culture was transferred to 96-wel plates with wel volumes of 2.2 ml for use
on the handler, and 1 ml was transferred to a separate plate with wel volumes of 1.2
ml for storage. The culture plates were centrifuged to pelet the cels, then placed on
the liquid handler.
7.5.2. Plasmid purification 
A script was written and optimised which instructed the platform to resuspend the
cels, and perform a plasmid purifcation procedure using the magnetic bead-based kit
according to manufacturer's directions. Wash steps were performed in 0.01 KOH for the
plasmid purifcation procedures and 2 M KOH for the transformation steps. These
solutions were changed between runs. 
The DNA concentration was measured in the inbuilt platereader, alowing failed runs to
be identifed.
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7.5.3. Transformation
40 µl  of chemicaly competent cels prepared as in 7.4.2 were pipetted into a 96-wel
PCR plate on the cooled position of the handler, kept at 1°C. 0.5 µl DNA was
transferred by the liquid handler and incubated for 30 minutes, then the plate moved to
the PCR machine at 42°C for 30 seconds before being returned to the cooled position;
mimicking the heat-shock protocol described in section 7.4.2. 100 µl pre-warmed LB
media was added to the cels and they were returned to the PCR machine for a 2-hour
incubation at 37°C to recover.
Post-recovery, the cels were plated for observation and colony counting.
7.5.4. Semi-automated continuous culture
For the longer culture runs examined by fow cytometry, the handler was used to
sample cultures at regular intervals over the course of several days, and reinoculate
cultures into fresh media.
Cultures were grown, from seed stocks as described in 7.4.1, in 96-wel plates incubated
at 37°C and agitated at 300 rpm in a heated shaker inbuilt to the robotic platform.
Every 8 hours, the liquid handling platform inoculated a pre-warmed fresh plate of
media with a sample from each wel of the previous plate, and culture from the
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previous plate was diluted 1:100 in ddH2O and saved on a cooled position at 4°C, for
later analysis by fow cytometer.
It should be noted here that while the miniprep procedure in particular is built around
a kit which has since been discontinued by the manufacturer, it is easily adaptable to
use with other, similar kits. Since the time of use, they have been adapted – for
miniprep, PCR purifcation and transformation protocols – and applied to several other
liquid handlers within the Centre for Synthetic Biology and Innovation at Imperial
Colege and work with them is ongoing.
7.6. Analysis
7.6.1. Rifampicin reversion assays
Cels were transformed with appropriate plasmids and grown up overnight. Colonies
were picked as soon as they could be identifed, and used to inoculate 3 ml pre-warmed
LB in a glass test-tube. These were incubated at 37°C for 2 hours, then divided and
stored at -80°C in 20% glycerol in 1 ml aliquots. For the assays, cultures were
inoculated from stocks derived from independent colonies 1:1000 into 5 ml pre-warmed
auto-inducing media. These were incubated at 37°C with 222 rpm shaking for 18 hours.
OD at 600 nm was assessed for a 10× dilution of each culture, and the cultures were
normalised by addition of fresh auto-inducing media to an OD600 of 0.5. 2 ml of this
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normalised culture was plate on LB-agar plates containing rifampicin and incubated at
37°C for 16 hours before being scored.
7.6.2. Fluorimetry
Al samples for analysis by fuorescence plate reader were initialy cultured from
glycerol stocks of the relevant cel line. 3 µl of stock was taken and used to inoculate 3
ml pre-warmed (37°C) LB media in round-bottomed test tubes. These were cultured
overnight at 37°C, with shaking at 222 rpm before dilution 1:100 into 3 ml of pre-
warmed fresh LB media. After exponential phase was reached, cultures were diluted to
an OD at 600 nm of 0.1 and alowed to grow for 1 hour. 3 repeats of 200 µl of each
culture were distributed into a pre-warmed 96-wel plate. Where appropriate, inducer
was added at this stage. Plates were sealed with clear flm and loaded into the plate
reader, a BMG POLARstar Omega plate reader (BMG Labtech). Absorbance at 600
nm and fuorescence of the cels (485 nm/510 nm excitation/emission) were measured
every 5 minutes. The reader maintained a constant temperature of 37°C for the
duration of al assays, with shaking at 222 rpm between reads.
Fluorimetry data was analysed by determining background values via measurement of
blank media. This was subtracted from values of both fuorescence and absorbance.
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Fluorescence was then normalised with regard to cel density as measured by
absorbance at 600 nm. 
7.6.3. Flow cytometry
Cel culture was diluted 1:100 in 2 ml ddH2O. This was loaded onto a Becton-Dickinson
FACScan fow cytometer equipped with an Argon laser (excitation wavelength 488 nm),
and able to detect green fuorescence (emission wavelength parameter FL1 at 530 nm).
Gain was set to the maximum available level, to best differentiate fuorescent and non-
fuorescent cels. Data was colected according to manufacturer's instructions, and
analysed using either CyfLogic (Cyfogic.com) or Flowing Software
(fowingsoftware.com). Al gates and regions were defned post-sample colection.
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9. Appendices
9.1. Plate counts for automated plasmid segregation
9.1.1. Automated run
Figure 32: Colony counts of the semi-automated multi-copy mutation assays
Plasmids were purified from Bh156 and transformed into BL21 for plating and scoring.
Colony counts are separated into GFP +ve (fluorescent) and GFP -ve (non-fuorescent).
Top, left: pCD:GFP alone, no device plasmid. Top, right: pCD:GFP & pA3:T. Botom,
left: pCD:GFP & pA3:TA. Botom, right: pCD:GFP & pA3:T+A
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T7-AID fusion
Repeat 1 Repeat 2 Repeat 3
Culture
1 10 0 0.00% 9 9 50.00% #DIV/0!
2 30 0 0.00% 7 0 0.00% #DIV/0!
3 60 0 0.00% 15 0 0.00% 12 0 0.00%
4 20 0 0.00% 11 0 0.00% 35 0 0.00%
5 2 0 0.00% 17 0 0.00% 7 0 0.00%
6 18 0 0.00% 24 3 11.11% 5 0 0.00%
7 15 0 0.00% 2 0 0.00% 8 0 0.00%
8 127 0 0.00% 28 0 0.00% 16 0 0.00%
9 50 0 0.00% 18 0 0.00% #DIV/0!
10 34 4 10.53% 65 0 0.00% 24 0 0.00%
11 55 0 0.00% 120 0 0.00% 1 0 0.00%
12 14 0 0.00% 50 0 0.00% 3 0 0.00%
13 3 0 0.00% 3 0 0.00% #DIV/0!
14 85 0 0.00% #DIV/0! 4 3 42.86%
15 21 0 0.00% #DIV/0! #DIV/0!
16 #DIV/0! 1 0 0.00% 11 0 0.00%
17 48 0 0.00% #DIV/0! 13 0 0.00%
18 112 0 0.00% 12 0 0.00% 7 0 0.00%
19 51 0 0.00% 4 0 0.00% 5 0 0.00%
20 20 0 0.00% 8 0 0.00% 55 0 0.00%
21 68 0 0.00% #DIV/0! 1 0 0.00%
22 91 0 0.00% 59 0 0.00% 29 0 0.00%
23 39 1 2.50% 43 0 0.00% #DIV/0!
24 2 0 0.00% 2 0 0.00% 31 0 0.00%
Totals 975 5 0.51% 498 12 2.35% 267 3 1.11%
GFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-ve
Repeat 1 Repeat 2 Repeat 3
Culture
1 #DIV/0! 9 0 0.00% 0 0 #DIV/0!
2 #DIV/0! 67 0 0.00% 57 0 0.00%
3 236 0 0.00% 106 0 0.00% 38 22 36.67%
4 158 0 0.00% 28 0 0.00% 21 21 50.00%
5 120 0 0.00% 104 0 0.00% #DIV/0!
6 #DIV/0! 134 22 14.10% 40 0 0.00%
7 1 0 0.00% 185 1 0.54% 105 0 0.00%
8 #DIV/0! 80 0 0.00% 196 9 4.39%
9 197 0 0.00% #DIV/0! #DIV/0!
10 321 0 0.00% 31 3 8.82% 215 0 0.00%
11 105 0 0.00% 227 9 3.81% #DIV/0!
12 7 0 0.00% 12 0 0.00% 93 6 6.06%
13 258 0 0.00% 0 0 #DIV/0! 10 10 50.00%
14 #DIV/0! 84 40 32.26% #DIV/0!
15 100 0 0.00% 47 45 48.91% 232 0 0.00%
16 #DIV/0! 8 2 20.00% 1 0 0.00%
17 #DIV/0! 20 3 13.04% 167 77 31.56%
18 130 11 7.80% 92 0 0.00% 58 0 0.00%
19 #DIV/0! 36 0 0.00% 61 0 0.00%
20 266 0 0.00% 100 0 0.00% 266 21 7.32%
21 #DIV/0! 48 12 20.00% 101 18 15.13%
22 #DIV/0! 1 0 0.00% 9 0 0.00%
23 148 24 13.95% 73 23 23.96% #DIV/0!
24 7 0 0.00% 31 0 0.00% 104 0 0.00%
Totals 2054 35 1.68% 1523 160 9.51% 1774 184 9.40%
T7 RNAP & AID unfused
GFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-ve
T7 RNAP alone
Repeat 1 Repeat 2 Repeat 3
Culture
1 14 0 0.00% 46 0 0.00% #DIV/0!
2 62 0 0.00% #DIV/0! #DIV/0!
3 46 0 0.00% 1 0 0.00% #DIV/0!
4 1 0 0.00% 2 0 0.00% #DIV/0!
5 #DIV/0! 14 0 0.00% #DIV/0!
6 32 0 0.00% 45 0 0.00% #DIV/0!
7 46 0 0.00% 29 15 34.09% #DIV/0!
8 41 0 0.00% 13 0 0.00% #DIV/0!
9 24 0 0.00% 45 0 0.00% #DIV/0!
10 #DIV/0! 40 0 0.00% #DIV/0!
11 97 2 2.02% 95 0 0.00% #DIV/0!
12 3 0 0.00% 2 0 0.00% #DIV/0!
13 #DIV/0! 51 0 0.00% #DIV/0!
14 #DIV/0! 173 0 0.00% #DIV/0!
15 66 0 0.00% 20 0 0.00% #DIV/0!
16 #DIV/0! 2 0 0.00% #DIV/0!
17 117 0 0.00% 58 0 0.00% #DIV/0!
18 54 0 0.00% #DIV/0! #DIV/0!
19 1 0 0.00% #DIV/0! #DIV/0!
20 93 1 1.06% 15 0 0.00% #DIV/0!
21 28 0 0.00% 8 0 0.00% #DIV/0!
22 14 0 0.00% 31 0 0.00% #DIV/0!
23 106 0 0.00% 13 13 50.00% #DIV/0!
24 38 0 0.00% 1 1 50.00% #DIV/0!
Totals 883 3 0.34% 704 29 3.96% 0 0 #DIV/0!
GFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-ve
Negative Control
Repeat 1 Repeat 2 Repeat 3
Culture
1 #DIV/0! 50 0 0.00% 19 2 9.52%
2 10 0 0.00% 28 0 0.00% 41 6 12.77%
3 61 0 0.00% 29 0 0.00% 13 0 0.00%
4 13 0 0.00% 7 0 0.00% #DIV/0!
5 13 0 0.00% 10 0 0.00% #DIV/0!
6 18 0 0.00% 8 0 0.00% 4 3 42.86%
7 20 0 0.00% 40 0 0.00% 18 3 14.29%
8 16 0 0.00% 28 0 0.00% 16 0 0.00%
9 14 0 0.00% 32 0 0.00% 29 0 0.00%
10 5 0 0.00% 3 0 0.00% #DIV/0!
11 #DIV/0! #DIV/0! #DIV/0!
12 6 0 0.00% 21 0 0.00% #DIV/0!
13 4 0 0.00% 12 0 0.00% 45 0 0.00%
14 1 0 0.00% #DIV/0! 99 0 0.00%
15 10 0 0.00% 26 0 0.00% #DIV/0!
16 5 0 0.00% #DIV/0! #DIV/0!
17 11 0 0.00% 16 0 0.00% #DIV/0!
18 20 0 0.00% #DIV/0! 1 0 0.00%
19 150 0 0.00% 2 0 0.00% #DIV/0!
20 51 0 0.00% 38 0 0.00% 2 0 0.00%
21 6 0 0.00% 1 0 0.00% 6 0 0.00%
22 3 0 0.00% 7 0 0.00% 9 0 0.00%
23 16 0 0.00% #DIV/0! #DIV/0!
24 47 0 0.00% 16 0 0.00% 19 0 0.00%
Totals 500 0 0.00% 374 0 0.00% 321 14 4.18%
GFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-veGFP+veGFP-ve% GFP-ve
9.1.2. Semi-automated run
Figure 33: Colony counts of the automated multi-copy mutation assays
Plasmids were purified from Bh156 and transformed into BL21 for plating and scoring.
Colony counts are separated into GFP +ve (fluorescent) and GFP -ve (non-
fluorescent). Top, pC5:GFP & pA3:TA. Botom, pC5:GFP & pA3:T+A
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T7-AID fusion
Repeat 1 Repeat 2 Repeat 3
Culture
1 6 0 0.00% 48 0 0.00% 74 0 0.00%
2 494 0 0.00% 218 2 0.91% 96 0 0.00%
3 661 7 1.05% 180 0 0.00% 351 0 0.00%
4 387 0 0.00% 338 5 1.46% 322 0 0.00%
5 1117 7 0.62% 696 0 0.00% 575 0 0.00%
6 110 0 0.00% 186 3 1.59% 137 0 0.00%
7 184 0 0.00% 548 0 0.00% 336 0 0.00%
8 186 0 0.00% 792 0 0.00% 838 0 0.00%
9 334 17 4.84% 1003 0 0.00% 276 5 1.78%
10 223 0 0.00% 287 5 1.71% 231 0 0.00%
11 16 0 0.00% 506 0 0.00% 460 0 0.00%
12 203 6 2.87% 193 0 0.00% 192 4 2.04%
13 504 0 0.00% 762 0 0.00% 1196 1 0.08%
14 970 4 0.41% 1119 0 0.00% 1325 0 0.00%
15 423 0 0.00% 73 0 0.00% 294 0 0.00%
16 229 0 0.00% 359 0 0.00% 879 0 0.00%
17 475 0 0.00% 344 0 0.00% 858 0 0.00%
18 257 0 0.00% 940 5 0.53% 225 0 0.00%
19 950 0 0.00% 403 0 0.00% 300 1 0.33%
20 1537 0 0.00% 1923 0 0.00% 997 0 0.00%
21 139 0 0.00% 1012 0 0.00% 1638 0 0.00%
22 476 0 0.00% 635 0 0.00% 433 0 0.00%
23 451 0 0.00% 1908 0 0.00% 654 0 0.00%
24 774 5 0.64% 668 3 0.45% 266 0 0.00%
Totals 11106 46 0.41% 15141 23 0.15% 12953 11 0.08%
GFP +ve GFP -ve % GFP -ve GFP +ve GFP -ve % GFP -ve GFP +ve GFP -ve % GFP -ve
Repeat 1 Repeat 2 Repeat 3
Culture
1 266 189 41.54% 2337 3 0.13% 943 0 0.00%
2 1723 29 1.66% 789 0 0.00% 1473 0 0.00%
3 1349 78 5.47% 1671 12 0.71% 1756 0 0.00%
4 757 0 0.00% 1769 4 0.23% 1376 0 0.00%
5 799 923 53.60% 1730 3 0.17% 2797 0 0.00%
6 767 23 2.91% 1605 0 0.00% 1586 0 0.00%
7 1896 280 12.87% 1603 0 0.00% 458 0 0.00%
8 1284 36 2.73% 904 0 0.00% 2463 0 0.00%
9 1179 471 28.55% 730 1 0.14% 1568 0 0.00%
10 911 322 26.12% 1265 30 2.32% 1158 0 0.00%
11 623 545 46.66% 1800 2 0.11% 1432 0 0.00%
12 316 72 18.56% 2070 0 0.00% 3919 0 0.00%
13 915 268 22.65% 2021 0 0.00% 154 0 0.00%
14 194 0 0.00% 830 0 0.00% 1111 0 0.00%
15 1619 6 0.37% 935 0 0.00% 0 0 #DIV/0!
16 861 112 11.51% 1785 0 0.00% 1112 0 0.00%
17 2253 370 14.11% 1198 0 0.00% 1638 0 0.00%
18 1564 23 1.45% 644 0 0.00% 3097 0 0.00%
19 3797 735 16.22% 284 0 0.00% 1545 0 0.00%
20 419 888 67.94% 981 0 0.00% 1158 0 0.00%
21 1415 347 19.69% 1440 0 0.00% 1446 28 1.90%
22 1003 702 41.17% 1181 0 0.00% 1761 0 0.00%
23 605 24 3.82% 1236 0 0.00% 1668 0 0.00%
24 1926 207 9.70% 0 0 #DIV/0! 0 0 #DIV/0!
Totals 28441 6650 18.95% 30808 55 0.18% 35619 28 0.08%
T7 RNAP & AID unfused
GFP +ve GFP -ve % GFP -ve GFP +ve GFP -ve % GFP -ve GFP +ve GFP -ve % GFP -ve
9.2. Automation script
9.2.1. Miniprep & transformation
156
Figure 34: The automation script for combined plasmid purification and transformation
9.3. Details of mutations detected by sequencing (4.3.3)
9.3.1. Mutation information
No. Mutation Sequence Traceposition
GFP
position
AA 
result
1 ATT–ATC F,-,6 203 42 Silent
2 TAC–TAT F,-,10 278 117 Silent
3 CTT–TTT F,-,2 293 124 Leu–Phe
4 GCG–GTG F,-,4 371 215 Ala–Val
5 AGT–AAT F,-,10 418 257 Ser–Asn
6 GTA–ATA F,-,8 438 277 Val–Ile
7 CAG–TAG F,-,7 438 280 Gln–STOP
8 CAG–TAG F,+,6 438 280 Gln–STOP
9 ACT–ATT F,-,3 445 290 Thr–Ile
10 ACA–ACG F,-,2 493 324 Silent
11 AGA–ATA F,-,2 534 365 Arg–Ile
12 AAC–AAT F,+,7 596 438 Silent
13 AGC–AGT F,-,8 686 525 Silent
14 AGC–AGT F,-,7 683 525 Silent
15 AGC–AGT F,+,6 683 525 Silent
16 AGC–AGT F,-,3 680 525 Silent
17 TAC–TAT F,+,8 763 600 Silent
18 ACA–ATA F,+,10 830 674 Thr–Ile
19 TAC–TAT F,-,1 867 711 Silent
Table 6: Further information on mutation events
Sequence key – X,Y,Z where X is F for the fusion, U for unfused T7-AID and T for T7
RNAP alone; Y is – or + corresponding to knockouts or fluorescent colonies; Z is the
sequence number from 1-10.
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9.3.2. Trace files
158
21
43
65
87
109
159
Figure 35: Mutation trace files
Trace files from sequencing of 
samples as described in section 4.3.3
1211
1413
1615
1817
19
9.4. DNA sequences of construct parts
9.4.1. Sequence information
NameDescription Sequence
PT7 T7 RNAP 
promoter
TAATACGACTCACTATA
PLac Lac-inducible 
promoter
AATTGTGAGCGGATAACAATTGACATTGTGAGCGGATAACAAGATACTGAGCACA
RBS32 Moderate-
strength RBS
TCACACAGGAAAG
RBS33 Weak RBS TCACACAGGAC
RBS34 Strong RBS AAAGAGGAGAAA
B0015
(XX)
Double 
transcriptional 
terminator 
CCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACG
CTCTCTACTAGAGTCACACTGGCTCACCTTCGGGTGGGCCTTTCTGCGTTTATA
AID Activation-
Induced 
Deaminase 
ATGGATAGCCTGCTGATGAATCGTCGCAAATTTCTGTATCAGTTTAAAAATGTGCGTTGGGCCAAAGGTCGTCGT
GAAACCTATCTGTGCTATGTTGTGAAACGTCGTGATAGCGCAACCAGCTTTAGCCTGGATTTTGGTTATCTGCGC
AATAAAAATGGTTGTCATGTGGAGCTGCTGTTTCTGCGTTATATTAGCGATTGGGATCTGGATCCGGGTCGTTGT
TATCGTGTTACCTGGTTTACCAGCTGGTCACCGTGTTATGACTGTGCACGTCATGTTGCAGATTTTCTGCGTGGT
AATCCGAATCTGAGCCTGCGTATTTTTACCGCACGTCTGTATTTTTGCGAAGATCGTAAAGCAGAACCGGAAGGT
CTGCGTCGTCTGCATCGTGCAGGTGTTCAGATTGCCATTATGACCTTTAAAGATTATTTTTATTGCTGGAATACCT
TTGTGGAAAATCATGAACGCACCTTTAAAGCATGGGAAGGCCTGCATGAAAATAGCGTTCGTCTGTCTCGCCAGC
TGCGTCGTATTCTGCTGCCGCTGTATGAAGTTGATGATCTGCGTGATGCCTTTCGTACCCTGGGTTTATAA
T7
RNAP
RNA Polymerase 
from T7 
bacteriophage
ATGAACACGATTAACATCGCTAAGAACGACTTCTCTGACATCGAACTGGCTGCTATCCCGTTCAACACTCTGGCTG
ACCATTACGGTGAGCGTTTAGCTCGCGAACAGTTGGCCCTTGAGCATGAGTCTTACGAGATGGGTGAAGCACGCT
TCCGCAAGATGTTTGAGCGTCAACTTAAAGCTGGTGAGGTTGCGGATAACGCTGCCGCCAAGCCTCTCATCACTA
CCCTACTCCCTAAGATGATTGCACGCATCAACGACTGGTTTGAGGAAGTGAAAGCTAAGCGCGGCAAGCGCCCGA
CAGCCTTCCAGTTCCTGCAAGAAATCAAGCCGGAAGCCGTAGCGTACATCACCATTAAGACCACTCTGGCTTGCC
TAACCAGTGCTGACAATACAACCGTTCAGGCTGTAGCAAGCGCAATCGGTCGGGCCATTGAGGACGAGGCTCGCT
TCGGTCGTATCCGTGACCTTGAAGCTAAGCACTTCAAGAAAAACGTTGAGGAACAACTCAACAAGCGCGTAGGGC
ACGTCTACAAGAAAGCATTTATGCAAGTTGTCGAGGCTGACATGCTCTCTAAGGGTCTACTCGGTGGCGAGGCGT
GGTCTTCGTGGCATAAGGAAGACTCTATTCATGTAGGAGTACGCTGCATCGAGATGCTCATTGAGTCAACCGGAA
TGGTTAGCTTACACCGCCAAAATGCTGGCGTAGTAGGTCAAGACTCTGAGACTATCGAACTCGCACCTGAATACG
CTGAGGCTATCGCAACCCGTGCAGGTGCGCTGGCTGGCATCTCTCCGATGTTCCAACCTTGCGTAGTTCCTCCTA
AGCCGTGGACTGGCATTACTGGTGGTGGCTATTGGGCTAACGGTCGTCGTCCTCTGGCGCTGGTGCGTACTCACA
GTAAGAAAGCACTGATGCGCTACGAAGACGTTTACATGCCTGAGGTGTACAAAGCGATTAACATTGCGCAAAACA
CCGCATGGAAAATCAACAAGAAAGTCCTAGCGGTCGCCAACGTAATCACCAAGTGGAAGCATTGTCCGGTCGAGG
ACATCCCTGCGATTGAGCGTGAAGAACTCCCGATGAAACCGGAAGACATCGACATGAATCCTGAGGCTCTCACCG
CGTGGAAACGTGCTGCCGCTGCTGTGTACCGCAAGGACAGGGCTCGCAAGTCTCGCCGTATCAGCCTTGAGTTC
ATGCTTGAGCAAGCCAATAAGTTTGCTAACCATAAGGCCATCTGGTTCCCTTACAACATGGACTGGCGCGGTCGT
GTTTACGCCGTGTCAATGTTCAACCCGCAAGGTAACGATATGACCAAAGGACTGCTTACGCTGGCGAAAGGTAAA
CCAATCGGTAAGGAAGGTTACTACTGGCTGAAAATCCACGGTGCAAACTGTGCGGGTGTCGATAAGGTTCCGTTC
CCTGAGCGCATCAAGTTCATTGAGGAAAACCACGAGAACATCATGGCTTGCGCTAAGTCTCCACTGGAGAACACT
TGGTGGGCTGAGCAAGATTCTCCGTTCTGCTTCCTTGCGTTCTGCTTTGAGTACGCTGGGGTACAGCACCACGGC
CTGAGCTATAACTGCTCCCTTCCGCTGGCGTTTGACGGGTCTTGCTCTGGCATCCAGCACTTCTCCGCGATGCTC
CGAGATGAGGTAGGTGGTCGCGCGGTTAACTTGCTTCCTAGTGAGACCGTTCAGGACATCTACGGGATTGTTGCT
AAGAAAGTCAACGAGATTCTACAAGCAGACGCAATCAATGGGACCGATAACGAAGTAGTTACCGTGACCGATGAG
AACACTGGTGAAATCTCTGAGAAAGTCAAGCTGGGCACTAAGGCACTGGCTGGTCAATGGCTGGCTCACGGTGT
TACTCGCAGTGTGACTAAGCGTTCAGTCATGACGCTGGCTTACGGGTCCAAAGAGTTCGGCTTCCGTCAACAAGT
GCTGGAAGATACCATTCAGCCAGCTATTGATTCCGGCAAGGGTCCGATGTTCACTCAGCCGAATCAGGCTGCTGG
ATACATGGCTAAGCTGATTTGGGAATCTGTGAGCGTGACGGTGGTAGCTGCGGTTGAAGCAATGAACTGGCTTAA
GTCTGCTGCTAAGCTGCTGGCTGCTGAGGTCAAAGATAAGAAGACTGGAGAGATTCTTCGCAAGCGTTGCGCTG
TGCATTGGGTAACTCCTGATGGTTTCCCTGTGTGGCAGGAATACAAGAAGCCTATTCAGACGCGCTTGAACCTGA
TGTTCCTCGGTCAGTTCCGCTTACAGCCTACCATTAACACCAACAAAGATAGCGAGATTGATGCACACAAACAGGA
GTCTGGTATCGCTCCTAACTTTGTACACAGCCAAGACGGTAGCCACCTTCGTAAGACTGTAGTGTGGGCACACGA
160
GAAGTACGGAATCGAATCTTTTGCACTGATTCACGACTCCTTCGGTACCATTCCGGCTGACGCTGCGAACCTGTT
CAAAGCAGTGCGCGAAACTATGGTTGACACATATGAGTCTTGTGATGTACTGGCTGATTTCTACGACCAGTTCGC
TGACCAGTTGCACGAGTCTCAATTGGACAAAATGCCAGCACTTCCGGCTAAAGGTAACTTGAACCTCCGTGACAT
CTTAGAGTCGGACTTCGCGTTCGCGTAA
T7-AID Fusion protein ATGGATAGCCTGCTGATGAATCGTCGCAAATTTCTGTATCAGTTTAAAAATGTGCGTTGGGCCAAAGGTCGTCGTGAAACCTATCTGTGCTATGTTGTGAAACGTCGTGATAGCGCAACCAGCTTTAGCCTGGATTTTGGTTATCTGCGC
AATAAAAATGGTTGTCATGTGGAGCTGCTGTTTCTGCGTTATATTAGCGATTGGGATCTGGATCCGGGTCGTTGT
TATCGTGTTACCTGGTTTACCAGCTGGTCACCGTGTTATGACTGTGCACGTCATGTTGCAGATTTTCTGCGTGGT
AATCCGAATCTGAGCCTGCGTATTTTTACCGCACGTCTGTATTTTTGCGAAGATCGTAAAGCAGAACCGGAAGGT
CTGCGTCGTCTGCATCGTGCAGGTGTTCAGATTGCCATTATGACCTTTAAAGATTATTTTTATTGCTGGAATACCT
TTGTGGAAAATCATGAACGCACCTTTAAAGCATGGGAAGGCCTGCATGAAAATAGCGTTCGTCTGTCTCGCCAGC
TGCGTCGTATTCTGCTGCCGCTGTATGAAGTTGATGATCTGCGTGATGCCTTTCGTACCCTGGGTTTAACCGGTC
AGGAAGTTGCATGCACCGCCGGCAACACGATTAACATCGCTAAGAACGACTTCTCTGACATCGAACTGGCTGCTA
TCCCGTTCAACACTCTGGCTGACCATTACGGTGAGCGTTTAGCTCGCGAACAGTTGGCCCTTGAGCATGAGTCTT
ACGAGATGGGTGAAGCACGCTTCCGCAAGATGTTTGAGCGTCAACTTAAAGCTGGTGAGGTTGCGGATAACGCT
GCCGCCAAGCCTCTCATCACTACCCTACTCCCTAAGATGATTGCACGCATCAACGACTGGTTTGAGGAAGTGAAA
GCTAAGCGCGGCAAGCGCCCGACAGCCTTCCAGTTCCTGCAAGAAATCAAGCCGGAAGCCGTAGCGTACATCACC
ATTAAGACCACTCTGGCTTGCCTAACCAGTGCTGACAATACAACCGTTCAGGCTGTAGCAAGCGCAATCGGTCGG
GCCATTGAGGACGAGGCTCGCTTCGGTCGTATCCGTGACCTTGAAGCTAAGCACTTCAAGAAAAACGTTGAGGAA
CAACTCAACAAGCGCGTAGGGCACGTCTACAAGAAAGCATTTATGCAAGTTGTCGAGGCTGACATGCTCTCTAAG
GGTCTACTCGGTGGCGAGGCGTGGTCTTCGTGGCATAAGGAAGACTCTATTCATGTAGGAGTACGCTGCATCGAG
ATGCTCATTGAGTCAACCGGAATGGTTAGCTTACACCGCCAAAATGCTGGCGTAGTAGGTCAAGACTCTGAGACT
ATCGAACTCGCACCTGAATACGCTGAGGCTATCGCAACCCGTGCAGGTGCGCTGGCTGGCATCTCTCCGATGTTC
CAACCTTGCGTAGTTCCTCCTAAGCCGTGGACTGGCATTACTGGTGGTGGCTATTGGGCTAACGGTCGTCGTCCT
CTGGCGCTGGTGCGTACTCACAGTAAGAAAGCACTGATGCGCTACGAAGACGTTTACATGCCTGAGGTGTACAAA
GCGATTAACATTGCGCAAAACACCGCATGGAAAATCAACAAGAAAGTCCTAGCGGTCGCCAACGTAATCACCAAG
TGGAAGCATTGTCCGGTCGAGGACATCCCTGCGATTGAGCGTGAAGAACTCCCGATGAAACCGGAAGACATCGAC
ATGAATCCTGAGGCTCTCACCGCGTGGAAACGTGCTGCCGCTGCTGTGTACCGCAAGGACAGGGCTCGCAAGTC
TCGCCGTATCAGCCTTGAGTTCATGCTTGAGCAAGCCAATAAGTTTGCTAACCATAAGGCCATCTGGTTCCCTTAC
AACATGGACTGGCGCGGTCGTGTTTACGCCGTGTCAATGTTCAACCCGCAAGGTAACGATATGACCAAAGGACTG
CTTACGCTGGCGAAAGGTAAACCAATCGGTAAGGAAGGTTACTACTGGCTGAAAATCCACGGTGCAAACTGTGCG
GGTGTCGATAAGGTTCCGTTCCCTGAGCGCATCAAGTTCATTGAGGAAAACCACGAGAACATCATGGCTTGCGCT
AAGTCTCCACTGGAGAACACTTGGTGGGCTGAGCAAGATTCTCCGTTCTGCTTCCTTGCGTTCTGCTTTGAGTAC
GCTGGGGTACAGCACCACGGCCTGAGCTATAACTGCTCCCTTCCGCTGGCGTTTGACGGGTCTTGCTCTGGCATC
CAGCACTTCTCCGCGATGCTCCGAGATGAGGTAGGTGGTCGCGCGGTTAACTTGCTTCCTAGTGAGACCGTTCAG
GACATCTACGGGATTGTTGCTAAGAAAGTCAACGAGATTCTACAAGCAGACGCAATCAATGGGACCGATAACGAA
GTAGTTACCGTGACCGATGAGAACACTGGTGAAATCTCTGAGAAAGTCAAGCTGGGCACTAAGGCACTGGCTGGT
CAATGGCTGGCTCACGGTGTTACTCGCAGTGTGACTAAGCGTTCAGTCATGACGCTGGCTTACGGGTCCAAAGAG
TTCGGCTTCCGTCAACAAGTGCTGGAAGATACCATTCAGCCAGCTATTGATTCCGGCAAGGGTCCGATGTTCACT
CAGCCGAATCAGGCTGCTGGATACATGGCTAAGCTGATTTGGGAATCTGTGAGCGTGACGGTGGTAGCTGCGGTT
GAAGCAATGAACTGGCTTAAGTCTGCTGCTAAGCTGCTGGCTGCTGAGGTCAAAGATAAGAAGACTGGAGAGATT
CTTCGCAAGCGTTGCGCTGTGCATTGGGTAACTCCTGATGGTTTCCCTGTGTGGCAGGAATACAAGAAGCCTATT
CAGACGCGCTTGAACCTGATGTTCCTCGGTCAGTTCCGCTTACAGCCTACCATTAACACCAACAAAGATAGCGAGA
TTGATGCACACAAACAGGAGTCTGGTATCGCTCCTAACTTTGTACACAGCCAAGACGGTAGCCACCTTCGTAAGAC
TGTAGTGTGGGCACACGAGAAGTACGGAATCGAATCTTTTGCACTGATTCACGACTCCTTCGGTACCATTCCGGC
TGACGCTGCGAACCTGTTCAAAGCAGTGCGCGAAACTATGGTTGACACATATGAGTCTTGTGATGTACTGGCTGA
TTTCTACGACCAGTTCGCTGACCAGTTGCACGAGTCTCAATTGGACAAAATGCCAGCACTTCCGGCTAAAGGTAA
CTTGAACCTCCGTGACATCTTAGAGTCGGACTTCGCGTTCGCGTAA
GFPmu
t3b 
Optimised Green 
Fluorescent 
Protein
ATGCGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCAC
AAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTG
GAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTCGGTTATGGTGTTCAATGCTTTGCGAGATACCCAGA
TCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTTCAAA
GATGACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAA
GGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTATACA
TCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTTC
AACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTC
CACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAACAGCTGC
TGGGATTACACATGGCATGGATGAACTATACAAATAATAA
XFP GFPmut3b with 
Y66H mutation 
ATGCGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCAC
AAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTG
GAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTCGGTCATGGTGTTCAATGCTTTGCGAGATACCCAG
ATCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTTCAA
AGATGACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAA
AGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTATAC
ATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTT
CAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGT
CCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAACAGCTG
CTGGGATTACACATGGCATGGATGAACTATACAAATAA
LasR Transcriptional 
activator from 
P. aeruginosa
ATGGCCTTGGTTGACGGTTTTCTTGAGCTGGAACGCTCAAGTGGAAAATTGGAGTGGAGCGCCATCCTCCAGAA
GATGGCGAGCGACCTTGGATTCTCGAAGATCCTGTTCGGCCTGTTGCCTAAGGACAGCCAGGACTACGAGAACGC
CTTCATCGTCGGCAACTACCCGGCCGCCTGGCGCGAGCATTACGACCGGGCTGGCTACGCGCGGGTCGACCCGAC
GGTCAGTCACTGTACCCAGAGCGTACTGCCGATTTTCTGGGAACCGTCCATCTACCAGACGCGAAAGCAGCACGA
GTTCTTCGAGGAAGCCTCGGCCGCCGGCCTGGTGTATGGGCTGACCATGCCGCTGCATGGTGCTCGCGGCGAAC
TCGGCGCGCTGAGCCTCAGCGTGGAAGCGGAAAACCGGGCCGAGGCCAACCGTTTCATAGAGTCGGTCCTGCCG
ACCCTGTGGATGCTCAAGGACTACGCACTGCAAAGCGGTGCCGGACTGGCCTTCGAACATCCGGTCAGCAAACCG
161
GTGGTTCTGACCAGCCGGGAGAAGGAAGTGTTGCAGTGGTGCGCCATCGGCAAGACCAGTTGGGAGATATCGGT
TATCTGCAACTGCTCGGAAGCCAATGTGAACTTCCATATGGGAAATATTCGGCGGAAGTTCGGTGTGACCTCCCG
CCGCGTAGCGGCCATTATGGCCGTTAATTTGGGTCTTATTACTCTCTAATAA
PLas AHL- and LasR-
dependent 
promoter
GACGCGGTTGCCCAAGCCGTTTCCGAAGGTGCCTCCTGAGCAGTTCAGATAGGTTGTCCGACCCCGAGTGGCAC
GGCAGAGTGCCA
HrpR Cooperative 
activator from 
P. syringae
ATGAGTACAGGCATCGATAAGGACGTCCGAGAGTGTTGGGGCGTAACTGCATTATCAGCGGGTCATCAAATTGCA
ATGAATAGCGCGTTTCTGGATATGGACTTGCTGTTGTGCGGGGAAACCGGCACCGGCAAGGACACACTGGCCAAC
CGCATTCACGAGTTGTCCAGCAGGTCGGGACCCTTTGTGGGCATGAACTGCGCCGCCATTCCCGAGTCGCTGGCA
GAGAGCCAGTTATTCGGTGTGGTCAACGGTGCATTCACCGGCGTATGCCGGGCTCGCGAGGGCTACATAGAGGCC
TCCAGTGGTGGCACCTTGTACCTGGATGAAATCGACAGCATGCCGTTGAGCCTGCAAGCCAAACTGCTGCGTGTG
TTGGAGAGTCGAGGTATCGAGCGTCTGGGCTCGACCGAATTTATCCCGGTGGATCTGCGGATCATTGCCTCGGCC
CAGCGGCCACTGGATGAACTGGTGGAACAAGGACTTTTCCGTCGCGACCTGTTTTTTCGGCTCAACGTGCTGAC
GCTTCACTTGCCAGCCTTGCGCAAACGTCGTGAACAGATCCTGCCATTGTTCGACCAGTTCACCCAGGGTATCGC
TGCCGAGTTCGGACGTCCCGCTCCTGCGCTGGACAGCGGGCGTGTGCAGCTGCTGCTCAGCCACGACTGGCCGG
GCAACATCCGCGAATTGAAGTCTGCGGCCAAGCGCTTCGTACTCGGCTTCCCCTTGCTGGGCGCCGACCCTGTGG
AAGCGCTTGACCCTGCCACGGGGCTGCGCACGCAAATGCGCATCATCGAGAAAATGCTCATCCAGGATGCCTTGA
AGCGGCACAGGCACAATTTCGACGCGGTGCTTCAGGAGTTGGAGTTGCCAAGACGCACCCTGTATCACCGCATGA
AGGAACTGGGAGTTGCAGCGCCGATCGCTGCGACGGCCGGGGTCTAA
HrpS Cooperative 
activator from 
P. syringae
ATGAGTCTTGATGAAAGGTTTGAGGATGATCTGGACGAGGAGCGGGTTCCGAATCTGGGGATAGTTGCCGAAAG
TATTTCGCAACTGGGTATCGACGTGCTGCTATCGGGTGAGACCGGCACGGGCAAAGACACGATTGCCCGACGGAT
TCATGAGATGTCAGGCCGCAAAGGGCGCCTGGTGGCGATGAATTGCGCGGCCATTCCGGAGTCCCTCGCCGAGA
GCGAGTTATTCGGCGTGGTCAGCGGTGCCTACACCGGCGCTGATCGCTCCAGAGTCGGTTATGTCGAAGCGGCGC
AGGGCGGCACGCTGTACCTGGATGAGATCGATAGCATGCCGCTGAGCCTGCAAGCCAAATTGCTGAGGGTGCTGG
AAACCCGAGCGCTTGAACGGCTGGGTTCGACGTCGACGATCAAGCTGGATATCTGCGTGATCGCCTCCGCCCAAT
GCTCGCTGGACGACGCCGTCGAGCGGGGGCAGTTTCGTCGCGATCTGTATTTTCGCCTGAACGTCCTGACACTCA
AGCTTCCTCCGCTACGTAACCAGTCTGATCGCATAGTTCCCCTGTTCACACGTTTTACGGCCGCCGCCGCGAGGG
AGCTCGGTGTTCCCGTTCCCGATGTTTGCCCACTGCTGCACAAAGTGCTGCTGGGCCACGACTGGCCCGGCAATA
TCCGTGAGCTCAAGGCGGCAGCCAAACGCCATGTGCTGGGTTTCCCCTTGCTGGGCGCCGAGCCGCAGGGCGAA
GAGCACTTGGCCTGTGGGCTCAAATCGCAATTGCGAGTGATCGAAAAAGCCCTGATTCAGGAGTCGCTCAAGCG
CCACGACAATTGTGTGGATTCGGTAAGCCTGGAACTGGACGTGCCACGCCGTACGCTCTATCGACGCATCAAAGA
ATTGCAGATCTAA
PHrp HrpR- and 
HrpS-dependent 
promoter
GCCGGATTATGTCCGCTGAGTGGGTCACGGTCCCGGATCAGTTCCCTTGCGAAGCTGACCGATGTTTTTGTGCCA
AAAGCTGTTGTGGCAAAAAACGGTTTGCGCAAAGTTTTGTATTACAAAGAATTTCACATTTTAAAATATCTTTATA
AATCAATCAGTTATTTCTATTTTTAAGCTGGCATGGTTATCGCTATAGGGCTTGTAC
kanR Kanamycin 
resistance
ATGAGCCATATTCAACGGGAAACGTCTTGCTCCAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGGT
ATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAG
AGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGA
CGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGAT
CCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGT
GTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAG
GCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAA
CAAGTCTGGAAAGAAATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTT
GATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACC
AGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGG
TATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAA
Table 7: DNA sequences of parts and plasmids used in this work
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